thursday
novemb
erato
c
hall
meet
expert
optim
durat
adjuv
endocrin
treatment
breast
cancer
stephen
johnston
thursday
novemb
terpsichor
hall
lectur
way
overcom
resist
endocrin
therapi
breast
cancer
stephen
johnston
friday
novemb
erato
ab
lectur
anthracyclin
remain
compon
adjuv
chemotherapi
breast
cancer
norman
wolmark
luca
gianni
larri
norton
thoma
suter
gianni
bonadonna
gabriel
n
hortobagyi
purpos
review
data
relat
anthracyclin
adjuv
treatment
earli
breast
cancer
design
report
seminar
futur
anthracyclin
adjuv
treatment
breast
cancer
consid
particular
question
whether
anthracyclin
discard
replac
taxan
address
result
accumul
data
larg
random
trial
indic
genet
marker
may
role
predict
sensit
cytotox
drug
howev
reliabl
valid
test
avail
predict
sensit
anthracyclin
particular
topoisomeras
ii
alpha
amplif
andor
delet
especi
conjunct
human
epiderm
growth
factor
amplif
propos
fulfil
role
data
need
current
one
publish
trial
shown
regimen
may
superior
regimen
sever
trial
indic
combin
includ
anthracyclin
taxan
may
better
still
studi
aim
optim
anthracyclin
taxan
combin
integr
biolog
agent
seem
way
forward
valid
test
determin
whether
anthracyclin
greater
benefit
agent
individu
patient
conclus
anthracyclin
extens
test
clinic
trial
span
sever
decad
current
insuffici
data
recommend
replac
adjuv
treatment
breast
cancer
j
clin
oncol
copyright
american
societi
clinic
oncolog
friday
novemb
erato
c
lectur
breast
cancer
screen
wendi
chen
saturday
novemb
erato
ab
lectur
optim
adjuv
therapi
patient
posit
diseas
valentina
guarneri
express
amplifi
breast
tumor
confer
aggress
clinic
behaviour
introduct
monoclon
antibodi
trastuzumab
led
substanti
improv
prognosi
adjuv
set
result
six
phase
iii
random
trial
publish
report
far
explor
benefit
ad
trastuzumab
chemotherapi
differ
administr
trastuzumab
term
schedul
time
durat
test
overal
trial
includ
women
posit
breast
cancer
five
trial
demonstr
superior
ad
trastuzumab
chemotherapi
compar
chemotherapi
alon
therefor
trastuzumab
essenti
compon
adjuv
treatment
plan
posit
diseas
howev
sever
issu
deserv
attent
first
adjuv
trastuzumab
commonli
prescrib
breast
cancer
patient
irrespect
nodal
statu
major
patient
enrol
adjuv
trastuzumab
trial
nodal
involv
moreov
data
patient
node
neg
diseas
tumor
size
less
cm
avail
grow
bodi
literatur
show
patient
tumor
higher
rate
recurr
compar
tumor
data
indirectli
suggest
potenti
benefit
trastuzumab
base
therapi
patient
howev
sinc
popul
includ
adjuv
trial
optim
adjuv
therapi
still
defin
perspect
cardiac
safeti
issu
appear
even
import
spite
appli
care
patient
select
respect
cardiac
function
cardiac
morbid
symptomat
asymptomat
cardiac
dysfunct
report
major
larg
trastuzumab
adjuv
trial
particular
even
revers
major
case
clinic
impact
asymptomat
lvef
declin
long
term
cardiac
morbid
morbl
still
unknown
optim
trastuzumab
durat
still
matter
debat
choic
year
administr
adjuv
trial
empir
basi
data
arm
hera
still
lack
explor
potenti
less
toxic
regimen
remain
major
clinic
issu
sever
larg
random
trial
explor
shorter
trastuzumab
durat
ongo
across
sever
european
countri
phare
trial
franc
sold
trial
finland
north
european
countri
persephon
trial
uk
trial
itali
agent
evalu
adjuv
therapi
posit
breast
cancer
dual
tk
inhibitor
lapatinib
current
approv
treatment
metastat
breast
cancer
fail
trastuzumab
therapi
larg
phase
iii
random
adjuv
studi
allto
trial
complet
accrual
neratinib
tk
inhibitor
evalu
larg
random
doubl
blind
adjuv
studi
patient
complet
adjuv
trastuzumab
longer
year
free
recurr
friday
novemb
erato
ab
lectur
radiotherapi
breast
cancer
innov
approach
centuri
jeffrey
tobia
behalf
targti
trialist
group
background
follow
breast
conserv
surgeri
local
recurr
occur
within
index
quadrant
despit
presenc
multicentr
cancer
elsewher
breast
therefor
felt
restrict
radiat
therapi
tumour
bed
might
adequ
select
patient
earli
breast
cancer
potenti
advantag
might
possibl
deliv
form
target
irradi
singl
treatment
definit
surgic
excis
gener
anaesthet
approach
would
potenti
signific
benefit
patient
also
healthcar
system
method
safe
pilot
new
techniqu
singl
dose
target
radiotherapi
targit
use
intrabeam
first
patient
treat
uch
pilot
studi
publish
launch
trial
http
march
femal
patient
year
localis
invas
ductal
breast
carcinoma
suitabl
breast
conserv
surgeri
randomli
alloc
receiv
either
targit
ie
radiotherapi
whole
breast
extern
beam
radiotherapi
ebrt
postop
discoveri
predefin
factor
eg
lobular
carcinoma
could
trigger
addit
ebrt
targit
prove
necessari
opinion
supervis
team
case
word
patient
randomli
alloc
targit
arm
addit
ebrt
given
primari
outcom
measur
studi
analys
margin
local
recurr
conserv
breast
patient
could
treat
targit
definit
surgic
procedur
group
histolog
assess
excis
specimen
group
either
polici
accept
within
trial
protocol
find
patient
random
intern
centr
year
studi
enough
patient
median
follow
year
detect
origin
margin
power
confid
median
age
yr
iqr
median
tumour
size
iqr
lymph
node
involv
overal
number
complic
major
toxic
targit
vs
ebrt
p
equival
radiotherapi
toxic
rtog
grade
lower
targit
group
vs
p
combin
treatment
ad
approx
min
overal
oper
time
avoid
visit
centr
treatment
preced
least
one
visit
radiotherapi
treatment
plan
period
year
signific
differ
estim
local
recurr
conserv
breast
targit
ebrt
ci
vs
ci
p
interpret
targit
approach
safe
local
recurr
singl
dose
targit
compar
ebrt
deliv
sever
week
select
group
patient
patient
requir
addit
ebrt
long
term
obvious
essenti
continu
regard
initi
result
extrem
encourag
particularli
sinc
breast
cancer
common
condit
singl
diagnosi
constitut
substanti
portion
workload
radiotherapi
depart
thursday
novemb
terpsichor
scientif
symposium
n
ovel
therapeut
approach
breast
cancer
fabric
pathway
activ
around
breast
cancer
sever
molecular
alter
lead
mtor
activ
includ
tyrosin
kinas
activ
egfr
mutat
pten
loss
preclin
studi
suggest
aberr
mtor
pathway
activ
could
lead
resist
endocrin
therapi
trastuzumab
base
background
mtor
inhibitor
evalu
either
singl
agent
combin
standard
provid
singl
agent
everolimu
induc
respons
rate
metastat
breast
cancer
patient
administ
daili
two
phase
trial
evalu
toler
efficaci
ad
everolimu
trastuzumab
chemotherapi
two
trial
report
high
rate
object
respons
patient
refractori
chemotherapi
trastuzumab
final
one
phase
ii
random
trial
evalu
benefit
ad
everolimu
aromatas
inhibitor
phase
ii
random
trial
everolimu
arm
associ
increas
rate
clinic
respons
p
increas
rate
normalis
base
earli
trial
three
registr
phase
iii
trial
develop
name
bolero
ii
iii
two
major
question
aris
regard
optim
use
mtor
inhibitor
first
preliminari
data
suggest
mutat
exon
could
predict
efficaci
everolimu
combin
letrozol
second
sever
team
describ
inhibit
mtor
could
lead
feedback
loop
turn
activ
intracellular
kinas
base
observ
combin
mtor
inhibitor
inhibitor
evalu
report
present
preliminari
signal
efficaci
thursday
novemb
terpsichor
scientif
symposium
n
ovel
therapeut
approach
breast
cancer
david
mile
concept
angiogenesi
target
treatment
cancer
consid
mani
year
biolog
molecular
identif
one
key
mediat
angiogenesi
vascular
endotheli
growth
factor
vegf
clinic
trial
field
truli
feasibl
inhibit
vegf
use
antibodi
ligand
receptor
inhibitor
vegf
receptor
tyrosin
kinas
tki
lead
prune
vasculatur
normalis
may
lead
increas
deliveri
convent
agent
chang
observ
anim
model
patient
use
dynam
contrast
mri
randomis
phase
iii
studi
test
antibodi
vegf
bevacizumab
addit
weekli
taxol
yield
improv
respons
rate
reduc
risk
diseas
progress
pf
improv
overal
surviv
observ
two
subsequ
placebo
control
phase
iii
studi
differ
chemotherapi
regimen
avado
also
demonstr
improv
respons
rate
modest
improv
pf
improv
overal
surviv
consequ
these
find
oncolog
drug
advisori
committe
odac
vote
extens
acceler
approv
bevacizumab
avastin
breast
cancer
inde
vote
remov
metastat
breast
cancer
avastin
label
deliber
us
food
drug
administr
current
await
trial
vegf
tki
disappoint
sorfenib
increas
pf
ad
capecitabin
trial
sunitinib
demonstr
benefit
trial
abandon
earli
like
neg
outcom
studi
examin
role
bevacizumab
adjuv
set
either
complet
recruit
beatric
ongo
beth
clearli
result
studi
await
interest
neg
result
adjuv
colorect
studi
question
understand
diseas
depend
vegf
consid
dynam
imag
studi
aspect
clinic
trial
data
clear
modul
tumour
vasculatur
vegf
inhibit
profound
potenti
benefici
effect
term
tumour
control
incumb
research
commun
increas
understand
agent
may
better
target
like
benefit
either
term
clinic
characterist
molecular
predictor
respons
similarli
understand
vegf
depend
diseas
must
better
understood
design
relev
clinic
trial
adjuv
set
thursday
novemb
terpsichor
scientif
symposium
n
ovel
therapeut
approach
breast
cancer
nichola
turner
poli
polymeras
parp
enzym
promot
dna
break
repair
function
break
sensor
facilit
break
repair
break
repair
requir
repair
dna
damag
multipl
chemotherapi
drug
ioniz
radiat
multipl
chemic
inhibitor
parp
develop
initi
chemotherapi
radiat
sensit
clinic
develop
parp
inhibitor
indic
anticanc
agent
proceed
cautious
concern
toxic
uncertainti
whether
approach
would
increas
therapeut
window
chang
identif
cancer
defect
dna
break
repair
homolog
recombin
hr
intrins
sensit
parp
inhibitor
sensit
often
term
synthet
lethal
reflect
observ
cell
normal
dna
repair
pathway
intrins
sensit
parp
inhibitor
given
singl
agent
dna
repair
pathway
particular
hr
abl
compens
impair
break
repair
howev
cell
defici
hr
unabl
compens
parp
dna
damag
cell
becam
highli
sensit
parp
inhibitor
tumor
suppressor
protein
requir
hr
consequ
cell
line
defici
protein
highli
sensit
parp
inhibitor
crucial
parp
inhibitor
synthet
lethal
target
defici
dna
repair
target
cancer
cell
establish
substanti
therapeut
window
demonstr
breast
ovarian
cancer
aris
women
mutat
highli
sensit
parp
inhibitor
olaparib
minim
toxic
brought
parp
inhibitor
forefront
cancer
although
mutat
account
breast
cancer
potenti
multipl
way
hr
may
lost
somat
cancer
breast
cancer
promot
methyl
occur
cancer
result
loss
express
express
also
suppress
commonli
subtyp
breast
cancer
suppress
cancer
may
potenti
explain
sensit
breast
cancer
combin
parp
inhibitor
combin
gemcitabin
carboplatin
recent
also
shown
vitro
phosphatas
pten
unexpect
nuclear
role
requir
normal
hr
potenti
open
parp
inhibitor
cancer
loss
pten
homozyg
delet
mutat
uncertainti
exist
whether
parp
inhibitor
best
use
singl
agent
combin
chemotherapi
possibl
combin
parp
inhibitor
chemotherapi
may
maxim
potenti
parp
inhibitor
clinic
research
requir
establish
whether
clinic
meaning
differ
multipl
parp
inhibitor
clinic
develop
establish
long
term
toxic
associ
parp
inhibit
friday
novemb
erato
ab
lectur
excel
cancer
care
role
nice
fergu
macbeth
reput
nice
mani
quarter
organis
ration
deni
access
new
cancer
medicin
implic
therefor
block
provid
excel
cancer
care
england
wale
caricatur
perhap
understand
unfair
eleven
year
sinc
incept
provid
broad
sweep
guidanc
nation
health
servic
clinic
cost
effect
care
cancer
patient
contribut
significantli
success
drive
improv
servic
across
countri
publish
ten
cancer
servic
guidanc
document
improv
outcom
cancer
give
blueprint
servic
specif
cancer
configur
deliv
seven
clinic
guidelin
produc
four
current
develop
two
metastat
spinal
cord
compress
metastat
malign
diseas
unknown
primari
origin
perhap
first
time
common
often
neglect
condit
address
systemat
nation
guidelin
apprais
cancer
drug
controversi
year
decis
made
individu
drug
specif
indic
great
major
posit
support
number
also
recommend
use
specif
patient
subset
research
rel
small
proport
recommend
use
nice
apprais
guidanc
associ
fund
direct
ensur
drug
must
fund
made
avail
result
signific
new
invest
direct
cancer
care
clearli
challeng
nh
provid
mani
latest
often
expens
new
drug
mani
refus
nice
recent
high
cost
limit
effect
nice
past
two
year
allow
committe
greater
freedom
end
life
medicin
consid
govern
encourag
compani
offer
patient
access
scheme
provid
free
subsidis
drug
limit
period
effect
reduc
price
allow
nice
approv
nice
strong
reput
within
uk
abroad
produc
clear
evid
base
guidanc
decis
may
sometim
controversi
process
robust
transpar
engag
health
profession
patient
stage
made
continu
make
import
contribut
cancer
care
deliv
saturday
novemb
erato
ab
intern
journal
cancer
session
cancer
prevent
lutz
gissman
saturday
novemb
erato
ab
intern
journal
cancer
session
cancer
prevent
cornelia
ulrich
energi
balanc
compon
physic
activ
bodi
weight
certain
play
role
primari
prevent
cancer
may
also
impact
tertiari
prevent
affect
prognosi
cancer
patient
low
level
physic
activ
overweight
obes
associ
variou
type
cancer
particularli
colorectum
postmenopaus
breast
physic
activ
colorectum
postmenopaus
breast
liver
esophagu
obes
possibl
mechan
includ
effect
inflamm
immun
function
growth
factor
insulin
resist
steroid
hormon
vitamin
level
lipid
metabol
yet
unexplor
possibl
mechan
link
energi
balanc
cancer
risk
includ
effect
dna
repair
capac
defect
dna
repair
function
clearli
carcinogen
intrigu
preliminari
evid
suggest
regular
exercis
result
adapt
respons
enhanc
antioxid
defens
dna
repair
among
cancer
patient
initi
clinic
studi
illustr
benefit
exercis
train
qualiti
life
fatigu
well
fit
level
strength
cachexia
epidemiolog
studi
also
suggest
posit
influenc
physic
activ
prognosi
particularli
colorect
cancer
patient
howev
mani
question
remain
regard
causal
associ
interrelationship
exercis
bodi
weight
appropri
type
time
exercis
train
cancer
patient
maximum
benefit
minim
risk
saturday
novemb
erato
ab
intern
journal
cancer
session
cancer
prevent
magnu
von
knebel
doeberitz
cancer
biomark
defin
alter
cancer
cell
either
dna
rna
protein
metabolit
level
ideal
alter
distinct
express
pattern
select
occur
cancer
cell
interest
surround
cell
tissu
enabl
unequivoc
identif
even
isol
cancer
cell
tissu
biopsi
clinic
sampl
mechanist
understand
molecular
pathway
lead
cell
transform
metastat
spread
allow
defin
candid
biomark
base
evid
base
molecular
hypothes
distinct
cancer
may
occur
prevent
cervic
cancer
earli
detect
sinc
earli
success
paradigm
success
cancer
earli
detect
prevent
program
pap
test
howev
hamper
import
technic
limit
recent
advanc
molecular
understand
harmless
progress
neoplast
lesion
allow
defin
novel
biomark
appear
resolv
sever
shortcom
current
use
earli
detect
techniqu
cervic
cancer
screen
recent
research
allow
definemolecular
mechan
mediat
switch
harmless
transient
product
potenti
danger
transform
base
shift
epigenet
methyl
pattern
basal
squamou
epitheli
cell
overexpress
hpv
gene
trigger
initi
cellular
transformationth
cyclin
depend
kinas
inhibitor
strongli
upon
deregul
express
viral
oncogen
epitheli
stem
cell
basal
parabas
cell
layer
antibodi
direct
develop
use
highlight
cell
histolog
section
cytolog
sampl
also
measur
amount
releas
dissolv
cell
collect
cervic
sampl
mani
clinic
studi
shown
novel
biomark
concept
substanti
improv
sensit
specif
current
cervic
cancer
screen
techniqu
confer
discuss
exampl
elucid
defin
molecular
pathway
cancer
allow
defin
molecular
biomark
inde
specif
neoplast
state
cell
clinic
potenti
clinic
impact
improv
futur
cancer
earli
detect
prevent
concept
saturday
novemb
terpsichor
uicc
session
cancer
stage
prognosi
era
person
cancer
treatment
mari
gospodarowicz
cancer
stage
essenti
element
classifi
measur
anatom
diseas
extent
diseas
measur
elementari
evalu
effect
intervent
shift
stage
earliest
indic
effect
screen
earli
detect
program
evalu
impact
practic
guidelin
qualiti
care
uicc
develop
tnm
cancer
stage
classif
intern
accept
clinic
relev
use
cancer
control
effort
uicc
tnm
prognost
factor
project
provid
evid
consensu
base
cancer
stage
classif
worldwid
use
work
across
world
necessit
engag
pay
attent
expertis
publish
evid
classif
adopt
opinion
leader
accept
engag
essenti
relev
clinic
practic
stage
must
signific
impact
cancer
outcom
select
treatment
methodswith
treatment
increasingli
tailor
patient
improv
outcom
prognost
factor
need
continu
reevalu
like
progress
occur
along
least
two
axe
first
improv
character
cancer
biolog
genet
molecular
characterist
individu
cancer
second
improv
character
diseas
extent
improv
molecular
imag
probe
knowledg
anatom
diseas
extent
alway
requir
minim
treatment
exposur
improv
diagnost
method
especi
accur
character
microscop
diseas
extent
could
help
defin
homogen
group
patient
similar
diseas
characterist
prognost
factor
specifi
diseas
knowledg
genet
molecular
factor
might
add
improv
predict
outcom
greater
individu
therapeut
intervent
howev
group
patient
similar
categori
continu
requir
assess
impact
new
technolog
patient
assess
new
therapi
outcom
uicc
tnm
prognost
factor
project
also
respond
grow
bodi
knowledg
grow
number
new
molecularli
defin
diseas
entiti
new
biomark
prognost
factor
essenti
defin
treatment
outcom
deal
challeng
impact
taxonomi
grant
support
cdc
tnm
project
engag
global
advisori
group
grow
number
nation
committe
cancer
stage
extend
collabor
initi
ajcc
cdc
cochran
collabor
partner
thursday
novemb
erato
ab
intern
journal
cancer
session
carcinogenesi
peter
lichter
thursday
novemb
erato
ab
intern
journal
cancer
session
carcinogenesi
jan
mollenhau
nowaday
tumor
profil
broad
repertoir
techniqu
virtual
everi
molecular
level
express
profil
mrna
level
complement
profil
method
mirna
rna
novel
breakthrough
proteom
allow
comprehens
determin
differenti
proteom
profil
cancer
final
techniqu
genom
sequenc
allow
genet
epigenet
profil
uncov
predispos
somat
alter
cancer
novel
sequenc
method
addit
allow
express
profil
mrna
rna
unpreced
resolut
gener
featur
profil
method
commonli
deliv
set
sever
hundr
molecul
differenti
activ
level
cancer
function
analysi
larg
candid
set
critic
import
discern
causal
correl
alter
causal
alter
subsequ
use
systemat
translat
novel
person
therapeut
approach
concept
cancer
stem
cell
profound
impact
question
profil
might
repres
promis
sourc
effort
perspect
somat
mutat
recov
genom
sequenc
repres
favor
start
point
assum
larg
invari
compar
bulk
cancer
cell
cancer
stem
cell
weigh
differ
vitro
function
genom
strategi
studi
gene
function
transient
transfect
method
rapidli
reach
threshold
becom
uneconom
contrast
construct
panel
stabl
cancer
cell
line
target
engin
gene
genet
alter
interest
provid
perman
resourc
systemat
studi
relev
aspect
cancer
cancer
growth
invas
drug
resist
directli
forward
vivo
studi
systemat
drug
screen
use
synthet
biolog
approach
engin
system
target
genet
manipul
cancer
cell
employ
techniqu
system
allow
construct
isogen
ie
genet
ident
stabl
cancer
cell
line
induc
constitut
upregul
one
two
target
gene
desir
permut
techniqu
allow
oper
critic
scale
come
molecular
profil
systemat
function
analys
prototyp
screen
select
profil
studi
set
candid
gene
melanoma
construct
panel
isogen
stabl
cell
line
target
function
genom
approach
deliv
numer
primari
hit
new
modul
cancer
growth
far
identifi
one
novel
oncogen
highli
upregul
across
variou
cancer
type
well
second
promis
drug
target
inactiv
latter
caus
synthet
lethal
select
cancer
cell
point
mutat
particular
oncogen
provid
exampl
translat
comprehens
molecular
profil
novel
convent
person
drug
target
via
systemat
function
genom
within
lundbeckfonden
center
excel
nanocan
effort
scale
systemat
identifi
new
drug
select
kill
activ
cancer
stem
cell
thursday
novemb
erato
ab
intern
journal
cancer
session
carcinogenesi
carsten
friday
novemb
terpsichor
educ
symposium
glioblastoma
vista
treatment
carsten
nieder
newli
diagnos
glioblastoma
landmark
phase
iii
trial
eortcncic
defin
current
standard
care
publish
stupp
et
al
postop
treatment
consist
extern
beam
radiotherapi
ebrt
total
dose
gy
fraction
concomit
administr
temozolomid
follow
chemotherapi
temozolomid
chemotherapi
might
enhanc
effect
radiotherapi
aim
either
addit
cell
kill
true
radiosensit
treat
microscop
tumour
base
principl
spatial
cooper
previou
studi
found
local
radiotherapi
field
appropri
radiotherapi
gy
better
lower
dose
dose
escal
ebrt
brachytherapi
fail
improv
surviv
stereotact
radiosurgeri
sr
studi
randomis
radiat
therapi
oncolog
group
rtog
trial
patient
recruit
ie
temozolomid
avail
one
arm
sr
given
singl
fraction
gy
depend
lesion
diamet
base
comput
tomographi
magnet
reson
imag
afterward
ebrt
gy
carmustin
administ
refer
treatment
arm
sr
associ
significantli
improv
surviv
therefor
ebrt
gy
still
current
standard
care
howev
unclear
whether
imag
technolog
use
time
truli
adequ
defin
sr
target
volum
given
high
precis
sharp
dose
achiev
sr
postop
chang
might
complic
glioma
target
volum
delin
current
studi
evalu
eg
positron
emiss
tomographi
variou
tracer
magnet
reson
spectroscopi
fraction
stereotact
radiotherapi
fsrt
might
allow
better
spare
surround
critic
structur
true
clinic
benefit
diseas
yet
adequ
identifi
radiotherapi
imrt
prerequisit
select
dose
escal
tumour
might
identifi
new
imag
method
hypothesi
test
biolog
aggress
imag
treat
select
higher
dose
recurr
glioblastoma
emerg
therapeut
option
select
patient
adequ
perform
statu
tumour
size
sr
fsrt
studi
randomis
trial
avail
rtog
dose
escal
trial
shown
sr
larg
recurr
tumour
requir
consider
dose
reduct
recommend
dose
target
measur
mm
gy
fsrt
might
improv
therapeut
ratio
case
pool
data
differ
studi
patient
review
group
demonstr
yield
surviv
surviv
without
addit
chemotherapi
median
valu
patient
karnofski
perform
statu
appear
higher
risk
earli
progress
appar
lesser
benefit
clinic
improv
observ
patient
seriou
late
toxic
uncommon
especi
convent
treatment
fsrt
even
fraction
size
gy
appear
well
toler
recurr
long
total
dose
limit
gy
agent
bevacizumab
might
expand
therapeut
armamentarium
role
conjunct
sr
fsrt
yet
defin
emerg
data
suggest
bevacizumab
might
improv
delay
radiat
toxic
perfus
impair
lead
necrosi
friday
novemb
terpsichor
educ
symposium
glioblastoma
vista
treatment
marc
sanson
friday
novemb
terpsichor
educ
symposium
glioblastoma
vista
treatment
charl
j
vecht
friday
novemb
terpsichor
educ
symposium
glioblastoma
vista
treatment
michael
weller
glioblastoma
malign
common
primari
intrins
brain
tumor
standard
care
patient
glioblastoma
includ
surgic
resect
whenev
feasibl
radiotherapi
chemotherapi
use
oral
alkyl
agent
temozolomid
anaplast
glioma
differenti
pure
astrocytoma
mix
oligoastrocytoma
pure
oligodendroglioma
surgeri
accept
standard
care
tumor
whether
radiotherapi
replac
chemotherapi
treatment
combin
chemotherapi
upfront
glioblastoma
current
explor
clinic
trial
dna
repair
enzym
enzym
methyltransferas
mgmt
antagon
genotox
effect
alkyl
agent
mgmt
promot
methyl
predict
favor
outcom
patient
glioblastoma
expos
chemotherapi
includ
temozolomid
nitrosourea
mgmt
promot
methyl
uniformli
result
mgmt
gene
silenc
thu
loss
mgmt
protein
express
remain
difficult
demonstr
nevertheless
biomark
mgmt
promot
methyl
may
futur
use
clinic
decis
make
least
newli
diagnos
glioblastoma
present
larg
use
stratifi
even
select
glioblastoma
patient
clinic
trial
instanc
centric
registr
trial
integrin
antagonist
cilengitid
limit
enrol
glioblastoma
patient
mgmt
promot
methyl
convers
glioblastoma
patient
lack
mgmt
promot
methyl
may
deriv
littl
benefit
temozolomid
chemotherapi
elig
european
trial
novel
agent
explor
newli
diagnos
set
combin
radiotherapi
alon
subtyp
glioma
anaplast
glioma
relev
mgmt
promot
methyl
might
extend
beyond
predict
chemosensit
could
reflect
distinct
molecular
profil
predict
respons
radiotherapi
well
broader
clinic
use
biomark
yet
feasibl
major
prerequisit
standard
test
met
difficulti
reproduc
across
laboratori
persist
standard
mgmt
test
requir
comparison
differ
technolog
across
laboratori
prospect
valid
valu
prognost
predict
effect
futur
clinic
trial
necessari
determin
subtyp
glioma
degre
mgmt
promot
methyl
predict
respons
specif
treatment
prognost
respons
genotox
therapi
broader
sens
whether
test
becom
routin
clinic
practic
present
except
repeatedli
confirm
prognost
valu
newli
diagnos
glioblastoma
prognost
predict
valu
mgmt
promot
methyl
patient
differ
type
glioma
treat
upfront
recurr
remain
controversi
friday
novemb
tersichor
educ
symposium
design
implement
clinic
trial
oncolog
silvia
camporesi
drug
develop
process
slow
time
consum
regulatori
burden
hamper
recruit
complet
clinic
trial
current
take
year
drug
discoveri
market
compar
averag
year
sinc
public
fda
concept
paper
titl
innov
stagnat
regulatori
agenc
us
europ
recogn
problem
respons
new
regulatori
guidelin
concern
earli
clinic
trial
issu
focus
pharmacodynam
endpoint
requir
lesser
amount
preclin
data
anim
guidelin
phase
trial
intent
treat
scientif
regulatori
point
view
therefor
press
need
updat
clinic
research
recogn
new
guidelin
clinic
trial
alon
go
solv
problem
clinic
research
requir
also
human
factor
particip
trial
fail
achiev
minimum
accrual
object
delay
studi
activ
identifi
major
culprit
behind
accrual
failur
current
fewer
elig
adult
patient
cancer
particip
clinic
trial
start
ethic
clinic
research
heavili
focus
protect
subject
understand
clinic
research
ethic
guidelin
written
aftermath
wwii
histor
condit
hold
anymor
data
demonstr
increas
particip
could
benefici
effect
advanc
medic
knowledg
ethic
foundat
clinic
research
also
consid
side
coin
name
patient
interest
particip
research
interest
advanc
sever
author
argu
favor
moral
oblig
particip
research
basi
argument
fair
reciproc
promot
public
good
biomed
knowledg
talk
propos
new
approach
base
libertarian
paternalist
lp
view
develop
cass
sunstein
richard
thaler
make
ethic
argument
concret
within
lp
perspect
subject
would
nudg
toward
particip
research
patient
meet
criteria
enrol
exhaust
standard
treatment
would
present
option
particip
clinic
trial
respect
autonom
decis
would
preserv
retain
possibl
opt
simpl
chang
initi
condit
could
strike
effect
practic
similarli
simpl
chang
default
option
context
organ
donat
show
phase
trial
offer
therapeut
benefit
particip
could
repres
paradigmat
case
shift
ethic
clinic
research
envisag
research
subject
parter
promot
common
good
biomed
knowledg
friday
novemb
tersichor
educ
symposium
design
implement
clinic
trial
oncolog
giusepp
curigliano
conduct
clinic
trial
europ
approach
state
crisi
layer
bureaucraci
particip
institut
govern
agenc
slow
review
process
concept
protocol
approv
trial
remain
uncomplet
poor
enrol
lack
interest
excess
administr
burden
inadequ
fund
current
protocol
initi
plagu
ineffici
overlap
oversight
lack
standard
collabor
research
group
industri
mani
step
review
process
redund
mani
oversight
committe
differ
object
respons
european
institut
oncolog
ieo
implement
strategi
improv
clinic
research
specif
chang
done
sever
area
speed
effici
design
launch
conduct
trial
innov
translat
scienc
trial
design
trial
priorit
accord
scientif
strength
accord
diseas
subpopul
select
support
complet
incent
patient
physician
particip
creat
scientif
steer
committe
strateg
scientif
committe
better
defin
trial
highest
prioriti
valid
biomark
mainten
tissu
bank
necessari
futur
person
medicin
studi
mani
establish
therapi
alreadi
place
hundr
potenti
therapi
arena
innov
trial
design
mandatori
main
approach
trial
design
breast
cancer
program
select
implement
research
accord
innov
trial
design
exampl
design
includ
multigroup
multistag
design
use
intermedi
outcom
test
new
agent
combin
singl
control
group
adapt
trial
design
use
bayesian
analysi
trial
allow
studi
group
elimin
patient
requir
reduc
predict
biomark
trial
stratifi
patient
accord
biomark
statu
progress
free
surviv
pf
trial
random
phase
ii
trial
simultan
multiag
trial
trial
design
subpopul
breast
cancer
patient
program
success
depend
increas
particip
patient
studi
obstacl
physician
particip
includ
time
requir
lack
academ
recognit
particip
inadequ
teach
mentor
clinic
trialist
inadequ
cost
reimburs
factor
address
involv
young
investig
mentor
career
develop
program
patient
obstacl
includ
fear
clinic
trial
variabl
coverag
care
expens
ignor
trial
option
complex
elig
requir
geograph
distanc
trial
site
potenti
limit
rectifi
straightforward
improv
expens
coverag
electron
tool
provid
inform
avail
trial
talk
specif
trial
present
inflammatori
breast
cancer
model
result
discuss
friday
novemb
tersichor
educ
symposium
design
implement
clinic
trial
oncolog
sara
gandini
statist
procedur
integr
result
sever
independ
studi
consid
combin
well
conduct
allow
object
assess
evid
tradit
narr
review
provid
precis
estim
treatment
effect
use
tool
investig
heterogen
use
gener
hypothes
futur
trial
studi
consist
trial
similar
goal
obtain
precis
estim
effect
main
difficulti
integr
result
variou
studi
regard
variabl
term
studi
design
method
employ
type
popul
perform
awar
problem
propos
number
guidelin
minim
impact
first
formal
protocol
written
specifi
exact
question
investig
describ
studi
includ
analysi
secondli
techniqu
use
investig
heterogen
valid
inclusionexclus
criteria
possibl
sourc
bia
includ
public
bia
thirdli
elig
studi
must
includ
data
must
free
due
select
exclus
criteria
fact
consciou
decis
made
exclud
alway
suspicion
done
order
achiev
desir
result
qualiti
report
quorom
confer
publish
checklist
suggest
item
includ
report
systemat
influenc
estim
treatment
effect
initi
also
act
catalyst
improv
method
conduct
fix
random
effect
model
use
combin
studi
former
base
hypothesi
true
magnitud
effect
assum
constant
latter
effect
vari
studi
analys
becom
increasingli
popular
medic
research
inform
efficaci
treatment
avail
number
clinic
studi
consid
separ
one
studi
may
either
small
limit
order
gener
conclus
effect
treatment
combin
find
across
studi
repres
attract
altern
strengthen
evid
treatment
efficaci
investig
reason
variabl
result
healthcar
manag
clinician
care
review
publish
balanc
assess
defici
like
becom
increasingli
import
way
resolv
therapeut
uncertainti
friday
novemb
tersichor
educ
symposium
design
implement
clinic
trial
oncolog
j
gordon
mcvie
saturday
novemb
terpsichor
b
educ
symposium
cancer
unknown
primari
site
frank
greco
john
hainsworth
cancer
unknown
primari
site
cup
syndrom
consist
mani
type
cancer
diagnost
techniqu
improv
patient
manag
continu
evolv
molecular
profil
tumor
may
aid
defin
primari
site
origin
sever
molecular
assay
reason
accur
recogn
known
primari
cancer
accuraci
clinic
util
assay
cup
classif
subject
recent
clinic
research
indirect
valid
studi
sever
assay
cup
correl
clinic
featur
immunohistochem
ihc
stain
pattern
suggest
assay
reason
accur
averag
posit
correl
one
studi
provid
direct
measur
accuraci
evalu
initi
biopsi
select
group
cup
patient
month
year
later
latent
primari
site
discov
thu
provid
direct
valid
assay
accur
tumor
determin
molecular
profil
add
standard
patholog
evalu
cup
defin
outcom
subset
patient
colorect
profil
complet
one
retrospect
evalu
continu
prospect
studi
biotheranost
molecular
assay
cancer
type
id
prospect
evalu
cup
patient
assay
success
perform
diagnost
biopsi
primari
site
predict
differ
site
intestin
cell
lung
breast
liver
ovari
pancrea
patient
singl
primari
site
predict
ihc
stain
group
molecular
assay
diagnosi
obtain
match
ihc
predict
correl
breast
lung
adenolarg
cell
notabl
patient
ihc
consist
possibl
primari
site
assay
match
one
cup
patient
colorect
diagnosi
respons
rate
chemotherapi
median
surviv
month
retrospect
studi
review
patient
cup
colorect
molecular
profil
standard
clinicopatholog
featur
frequent
consist
occult
colorect
primari
patient
receiv
either
first
regimen
use
colorect
cancer
respons
rate
median
surviv
month
molecular
profil
accur
predict
primari
site
origin
major
cup
patient
singl
primari
site
predict
ihc
stain
correl
molecular
profil
diagnosi
good
molecular
assay
may
necessari
major
patient
ihc
stain
specif
molecular
profil
assay
provid
addit
valuabl
inform
impact
therapi
cup
base
molecular
assay
diagnosi
appear
promis
particularli
colorect
subset
select
use
assay
concert
clinic
featur
ihc
stain
like
chang
therapeut
approach
mani
cup
patient
addit
prospect
studi
cup
molecular
profil
direct
therapi
determin
patient
outcom
improv
necessari
ongo
saturday
novemb
terpsichor
b
educ
symposium
cancer
unknown
primari
site
john
hainsworth
carcinoma
unknown
primari
site
cup
common
clinic
syndrom
account
approxim
cancer
diagnos
metastat
cancer
document
usual
basi
biopsi
metastat
lesion
clinic
patholog
evalu
indic
purpos
identifi
primari
site
tissu
origin
possibl
establish
whether
patient
fit
favor
treatment
subset
establish
extent
diseas
prognosi
initi
clinic
evalu
includ
complet
medic
histori
physic
examin
chemistri
profil
complet
blood
count
urinalysi
comput
tomographi
scan
chest
abdomen
pelvi
pet
scan
also
detect
occult
primari
tumor
although
benefit
incomplet
evalu
set
women
mammographi
men
measur
serum
psa
addit
evalu
base
clinic
signssymptom
specif
patholog
find
improv
method
diagnosi
excit
new
develop
manag
cup
discuss
complet
section
symposium
tradit
patholog
evalu
includ
assess
histolog
follow
pertin
immunohistochem
ihc
stain
although
excel
differenti
carcinoma
cell
lineag
identif
specif
adenocarcinoma
prostat
cancer
psa
stain
problemat
new
ihc
stain
somewhat
specif
although
still
requir
interpret
context
clinic
patholog
featur
addit
molecular
tumor
profil
intens
investig
current
undoubtedli
futur
use
establish
tissu
origin
mani
patient
even
primari
site
identifi
patient
categor
one
sever
treatabl
subset
basi
clinic
andor
patholog
featur
subset
includ
women
axillari
node
metastas
women
periton
carcinomatosi
young
men
featur
extragonad
germ
cell
tumor
squamou
carcinoma
involv
neck
node
squamou
carcinoma
involv
inguin
node
neuroendocrin
carcinoma
carcinoma
present
singl
metastat
lesion
men
elev
serum
tumor
level
psa
patient
colon
cancer
profil
detail
treatment
patient
subgroup
present
group
patient
fit
treatabl
subset
trial
empir
chemotherapi
current
treatment
standard
although
phase
iii
random
trial
exist
sever
modern
regimen
gener
accept
activ
either
best
support
care
older
regimen
regimen
includ
combin
taxaneplatinum
gemcitabineplatinum
gemcitabinetaxan
current
regimen
respons
rate
rang
report
seri
median
surviv
month
limit
experi
target
agent
exist
indic
activ
inhibitor
vegf
egf
pathway
howev
role
agent
target
other
current
undefin
saturday
novemb
terpsichor
b
educ
symposium
cancer
unknown
primari
site
john
hainsworth
increas
evid
support
abil
molecular
tumor
profil
correctli
identifi
tissu
origin
major
patient
cup
howev
littl
data
regard
use
put
diagnos
select
therapi
patient
inde
skeptic
establish
treatment
cancer
known
primari
site
effect
cup
patient
due
fundament
differ
tumor
biolog
howev
increas
anecdot
data
addit
retrospect
data
patient
colon
cancer
profil
suggest
least
portion
patient
cup
respond
treatment
predict
way
began
prospect
trial
evalu
use
molecular
assay
cancertyp
id
biotheranost
inc
identifi
tissu
origin
direct
treatment
patient
cup
patient
diagnosi
cup
biopsi
tumor
specimen
avail
elig
patient
specif
treatabl
subset
cup
exclud
patient
given
specif
tissu
origin
cancertyp
id
assay
treat
standard
treat
regimen
particular
type
cancer
without
specif
tissu
origin
treat
empir
cup
regimen
date
patient
enrol
molecular
profil
assay
perform
patient
specif
diagnos
render
patient
total
receiv
therapi
assay
unsuccess
due
inadequ
tissu
patient
remain
patient
receiv
therapi
reason
eg
rapidli
declin
perform
statu
refus
therapi
treatment
consid
urgent
initi
prior
assay
result
patient
receiv
therapi
specif
primari
site
identifi
molecular
profil
eighteen
differ
primari
site
identifi
assay
common
group
includ
pancrea
patient
colorect
urinari
bladder
cell
lung
cancer
ovari
patient
subset
current
rel
small
evalu
separ
treatment
efficaci
patient
colorect
cancer
profil
receiv
folfoxbevacizumab
patient
partial
respons
stabl
diseas
greater
six
month
median
overal
surviv
entir
group
patient
month
studi
ongo
goal
treat
suffici
patient
common
subset
abl
make
definit
statement
regard
efficaci
therapi
saturday
novemb
terpsichor
b
educ
symposium
cancer
unknown
primari
site
georg
pentheroudaki
cancer
unknown
primari
site
cup
rank
fourth
common
caus
cancer
death
repres
diagnost
manag
challeng
cup
regress
dormanc
primari
tumor
develop
earli
uncommon
system
metastas
resist
therapi
hallmark
heterogen
clinic
entiti
still
consensu
exist
whether
cup
simpli
group
metastat
tumor
unidentifi
primari
distinct
entiti
specif
geneticphenotyp
aberr
defin
primari
metastat
diseas
karyotyp
analys
well
studi
done
express
oncogen
gene
well
angiogenesi
effector
identifi
molecular
aberr
specif
cup
rather
metastat
malign
studi
show
frequent
express
oncoprotein
lack
activ
epiderm
growth
factor
mutat
amplif
uncommon
presenc
gene
mutat
highli
activ
angiogenesi
cup
inform
may
data
observ
sever
solid
tumor
known
primari
fail
identifi
molecular
signatur
latter
exist
probabl
consist
multigen
express
pattern
captur
studi
gene
protein
microarray
technolog
offer
promis
unravel
complex
genet
program
would
either
identifi
cup
primari
tissu
origin
instead
defin
molecular
signatur
confirm
one
two
hypothes
would
either
improv
primari
orient
therapi
develop
treatment
target
molecular
aberr
drive
neoplast
growthdissemin
saturday
novemb
terpsichor
b
educ
symposium
cancer
unknown
primari
site
gauri
varadhachari
carcinoma
unknown
primari
cup
account
new
cancer
challeng
heterogen
diseas
entiti
unmet
research
need
last
decad
increas
avail
sophist
diagnost
includ
newer
imag
immuhistochemistri
ihc
option
recent
molecular
profil
techniqu
although
innov
therapeut
intervent
lag
tradit
patient
cup
treat
empir
chemotherapi
doublet
least
two
potenti
approach
use
defin
cup
subset
improv
therapi
option
patient
approach
cup
tumor
may
evalu
express
molecular
marker
egfr
mutat
kra
other
yet
establish
approach
benefit
cup
patient
given
variabl
correl
marker
express
therapeut
respons
although
addit
insight
novel
target
drive
cup
biolog
may
allow
us
consid
appropri
test
altern
approach
attempt
use
ihc
gene
express
studi
help
identifi
cup
subset
molecular
profil
consist
put
site
origin
approach
could
potenti
leverag
substanti
develop
work
focus
tumor
recent
experi
latter
approach
encourag
last
year
come
recogn
new
favor
cup
subset
associ
profil
recogn
group
patient
import
appar
therapeut
implic
unlik
favor
cup
cancer
base
anatom
distribut
histopatholog
may
best
identifi
patholog
evalu
includ
ihc
molecular
profil
definit
patient
neg
colonoscopi
retrospect
prospect
studi
suggest
patient
immunohistochem
featur
molecular
profil
clinic
present
cours
resembl
colon
appendic
carcinoma
identifi
ck
posit
often
though
alway
ck
neg
ihc
molecular
profil
consist
profil
patient
known
metastat
colon
cancer
earli
work
suggest
patient
show
substanti
benefit
use
specif
therapeut
approach
develop
patient
metastat
colorect
tumor
limit
ihc
describ
known
colorect
cancer
includ
decreas
even
absent
ck
express
report
microsatellit
high
colon
tumor
poorli
differenti
tumor
also
begin
recogn
limit
profil
assay
best
approach
present
integr
cost
clinic
effect
algorithm
base
ihc
profil
complement
provid
patient
best
manag
option
friday
novemb
erato
ab
current
issu
oncolog
state
art
surgic
manag
colorect
liver
metastas
adam
thursday
novemb
terpsichor
lectur
adjuv
chemotherapi
stage
ii
colon
cancer
dirk
arnold
friday
novemb
erato
ab
current
issu
oncolog
state
art
surgic
manag
colorect
liver
metastas
thoma
gruenberg
thursday
novemb
erato
ab
lectur
organ
ac
colorect
cancer
prevent
earli
detect
updat
len
lichtenfeld
friday
novemb
terpsichor
plenari
lectur
appli
research
lesson
treatment
advanc
colon
cancer
john
l
marshal
treatment
colon
cancer
undergon
recent
revolut
move
world
median
surviv
month
approv
agent
us
overal
surviv
reach
nearli
year
claim
great
success
inde
pleas
must
recogn
yet
cure
diseas
still
use
trial
error
method
treat
patient
essenc
treatment
strategi
give
patient
drug
know
treatment
help
subset
patient
howev
enter
next
revolut
one
realiz
true
benefit
target
therapi
center
around
mutat
egfr
pathway
recogn
subset
patient
respond
egfr
agent
inform
result
posit
outcom
patient
receiv
drug
much
greater
chanc
benefit
longer
give
drug
patient
benefit
save
time
toxic
new
revolut
also
key
rapid
success
develop
next
gener
cancer
agent
test
today
importantli
must
tool
current
util
prime
among
tumor
sampl
newer
data
suggest
unless
control
condit
tumor
collect
accur
result
concept
ischemia
time
briefli
explor
overview
repres
small
fraction
novel
approach
investig
treatment
colon
cancer
success
target
egfr
vegf
pathway
increas
comprehens
need
person
medicin
treatment
patient
increas
depend
tumor
tissu
measur
specif
pathway
determin
pathway
tumor
depend
upon
oncogen
addict
ask
promis
futur
target
agent
actual
answer
play
key
role
find
right
patient
treat
futur
bright
highli
challeng
new
trial
design
requir
cooper
among
competitor
requir
goal
return
cure
cancer
mere
prolong
surviv
month
cure
expect
patient
societi
best
meet
goal
cancer
global
problem
like
local
genet
recogn
gastric
cancer
vari
around
world
true
colon
cancer
result
trial
perform
area
world
accur
reflect
result
region
thursday
novemb
erato
ab
current
issu
oncolog
organ
estro
new
challeng
head
neck
cancer
aisha
miah
background
xerostomia
commonest
late
toxic
rt
head
neck
imrt
dose
distribut
reduc
dose
deliv
parotid
gland
parsport
investig
role
imrt
reduc
xerostomia
patient
head
neck
cancer
method
parsport
trial
compar
two
radiotherapi
deliveri
method
treatment
patient
pharyng
tumour
patient
receiv
fraction
week
deliv
use
either
ct
plan
parallel
oppos
later
field
imrt
stratif
site
tumour
centr
primari
endpoint
incid
xerostomia
one
year
treatment
secondari
endpoint
includ
acut
toxic
ctcae
late
rtog
radiat
toxic
saliva
collect
attempt
parotid
gland
proport
patient
toxic
compar
use
exact
test
secondari
endpoint
signific
level
use
result
patient
rt
imrt
randomis
six
uk
centr
patient
oropharyng
tumour
hypopharyng
radiotherapi
given
primari
treatment
patient
patient
ajcc
stage
iii
diseas
median
month
iqr
twelv
month
xerostomia
score
observ
rt
imrt
patient
p
correspond
valu
month
p
rtog
scale
month
xerostomia
report
rt
vs
imrt
patient
p
month
incid
rt
vs
imrt
p
acut
radiotherapi
relat
fatigu
preval
imrt
group
vs
p
differ
acut
mucos
pain
score
seen
month
statist
signific
differ
seen
late
toxic
differ
overal
surviv
locoregion
control
rate
observ
conclus
spare
salivari
gland
use
imrt
preserv
salivari
flow
significantli
reduc
incid
xerostomia
patient
pharyng
tumour
c
nut
j
p
morden
sydenham
r
ahern
f
adab
k
harrington
jefferi
c
scrase
b
k
yap
e
hall
behalf
parsport
trial
manag
group
royal
marsden
hospit
nh
foundat
trust
london
unit
kingdom
institut
cancer
research
sutton
surrey
unit
kingdom
univers
hospit
north
staffordshir
stoke
trent
unit
kingdom
royal
marsden
hospit
nh
foundat
trust
london
unit
kingdom
addenbrook
hospit
nh
foundat
trust
cambridg
unit
kingdom
ipswich
hospit
nh
trust
ipswich
unit
kingdom
christi
nh
foundat
trust
manchest
unit
kingdom
thursday
novemb
erato
ab
current
issu
oncolog
organ
estro
new
challeng
head
neck
cancer
aisha
miah
thursday
novemb
erato
ab
current
issu
oncolog
organ
estro
new
challeng
head
neck
cancer
jen
overgaard
thursday
novemb
erato
ab
british
journal
surgeri
session
mileston
paper
rectal
cancer
bj
kjetil
progress
manag
outcom
patient
rectal
cancer
endeavour
across
disciplin
past
decad
obvious
success
deriv
build
brick
inform
puzzl
togeth
piec
scientif
progress
one
anoth
howev
major
leap
understand
principl
diseas
made
owe
work
mani
retrospect
view
paper
publish
british
journal
surgeri
past
half
centuri
may
identifi
studi
deem
particularli
valuabl
manag
rectal
cancer
evolv
studi
publish
surgic
journal
time
reveal
understand
diseas
evolv
also
scientif
approach
investig
develop
accord
web
scienc
paper
rectal
cancer
major
gener
surgic
journal
scarc
prior
earli
howev
past
decad
almost
exponenti
increas
paper
cover
topic
bj
take
definit
lead
term
number
paper
publish
articl
total
time
cite
citat
averag
citat
per
articl
per
articl
per
year
accumul
averag
citat
per
year
topic
addit
cite
paper
among
surgic
journal
topic
heald
et
al
mesorectum
rectal
cancer
surgeri
clue
pelvic
recurr
br
j
surg
follow
introduct
principl
total
mesorect
excis
tme
rectal
cancer
report
number
landmark
studi
demonstr
surviv
effect
train
implement
uniform
surgic
techniqu
well
hospit
surgeon
volum
patient
surviv
later
part
earli
paper
investig
prognost
factor
follow
includ
defin
circumferenti
resect
margin
role
time
adjuv
chemoradi
later
came
definit
mri
rectum
allow
preoper
identif
import
surgic
patholog
prognost
risk
factor
better
select
assess
patient
undergo
preoper
therapi
past
decad
seen
trial
compar
laparoscop
vs
open
techniqu
investig
bladder
sexual
dy
function
mesorect
excis
time
ampl
evid
surgic
scienc
evolv
retrospect
observ
studi
report
nation
registri
prospect
multicent
studi
random
clinic
trial
continu
clinic
investig
refin
research
question
new
mileston
paper
appear
manag
rectal
cancer
like
import
share
publish
bj
talk
illumin
mileston
made
rectal
cancer
past
decad
envis
present
select
paper
publish
bj
friday
novemb
terpsichor
plenari
lectur
hereditari
colorect
cancer
astrid
stormorken
introduct
colorect
cancer
crc
lead
caus
death
western
world
environment
factor
play
domin
role
aetiolog
crc
inherit
predisposit
major
risk
factor
famili
colorect
cancer
account
crc
caus
mutat
high
penetr
gene
discoveri
inherit
mutat
gene
associ
increas
risk
cancer
enabl
accur
risk
assess
target
surveil
prevent
measur
treatment
high
risk
person
purpos
lectur
give
brief
summari
hereditari
crc
syndrom
identifi
germlin
mutat
lynch
syndrom
hereditari
colorect
cancer
hnpcc
famili
adenomat
polyposi
fap
attenu
fap
afap
polyposi
map
syndrom
juvenil
polyposi
address
cancer
risk
individu
famili
cluster
crc
one
high
risk
cancer
syndrom
clinic
featur
genet
manag
recommend
cover
conclus
unlik
mani
type
tumour
tumour
colon
rectum
highli
access
use
endoscopi
surveil
prevent
develop
advanc
crc
also
implic
treatment
make
import
identifi
high
risk
individu
friday
novemb
terpsichor
b
educ
symposium
organ
esdo
gastric
junction
cardia
adenocarcinoma
light
expert
confer
hold
barcelona
june
join
congress
cervant
sever
drug
consid
activ
agent
treatment
advanc
gastric
cancer
case
oral
fluoropyrimidin
capecitabin
doxorubicin
epirubicin
cisplatin
oxaliplatin
docetaxel
irinnotecan
recent
antibodi
trastuzumab
howev
among
agent
cisplatin
docetaxel
trastuzumab
shown
better
therapi
trial
design
superior
endpoint
hand
oxaliplatin
capecitabin
found
accept
agent
noninferior
trial
role
anthracyclin
larg
debat
trial
use
singl
agent
show
low
respons
publish
eighti
respons
assess
mostli
perform
criteria
accept
use
liver
ultrasonographi
tool
data
publish
wagner
et
al
suggest
signific
surviv
benefit
anthracyclin
ad
combin
schedul
howev
base
upon
individu
data
patient
includ
trial
despit
epirubicin
use
ecf
regimen
give
consist
reproduc
result
sever
randomis
trial
includ
thousand
patient
royal
marsden
nevertheless
specif
valu
addit
epirubicin
difficult
assess
current
avail
inform
addit
docetaxel
convent
doublet
cisplatin
dcf
regimen
also
shown
offer
better
surviv
advanc
gastric
cancer
patient
howev
use
extend
due
perhap
toxic
constraint
especi
patient
poor
perform
statu
combin
platinum
agent
cisplatin
oxaliplatin
plu
capecitabin
could
consid
accept
practic
overexpress
trastuzumab
ad
chemotherapi
select
schedul
docetaxel
ad
third
drug
frequent
young
patient
good
perform
statu
dcf
ecf
variant
ecx
eox
could
accept
standard
compar
design
phase
iii
randomis
studi
current
practic
signific
proport
patient
advanc
gastric
cancer
progress
first
line
chemotherapi
good
perform
statu
german
random
trial
limit
number
patient
show
second
line
chemotherapi
irinotecan
could
improv
surviv
support
care
alon
trial
support
use
second
line
chemotherapi
good
perform
statu
individu
schedul
use
folfiri
docetaxel
combin
commonli
employ
could
prolong
diseas
control
advanc
gastric
cancer
patient
friday
novemb
terpsichor
b
educ
symposium
organ
esdo
gastric
junction
cardia
adenocarcinoma
light
expert
confer
hold
barcelona
june
join
congress
roberto
la
bianca
friday
novemb
terpsichor
b
educ
symposium
organ
esdo
gastric
junction
cardia
adenocarcinoma
light
expert
confer
hold
barcelona
june
join
congress
christoph
penna
friday
novemb
terpsichor
b
educ
symposium
organ
esdo
gastric
junction
cardia
adenocarcinoma
light
expert
confer
hold
barcelona
june
join
congress
philipp
rougier
surgeri
standard
main
treatment
without
metastas
howev
patient
develop
recurr
despit
resect
strategi
prevent
recurr
improv
overal
surviv
warant
adjuv
chemotherapi
act
standard
absenc
clearli
posit
trial
feasibl
patient
complic
poor
nuritionn
statu
result
less
benefit
overal
surviv
os
appropri
use
individu
data
hr
p
paoletti
x
et
al
jama
adjuv
crt
us
standard
seem
activ
limit
patient
excel
nutrit
statu
chemotherapi
poc
develop
low
efficaci
act
high
percentag
patient
unabl
receiv
abil
test
ct
efficaci
tumour
allow
cur
resect
rate
two
larg
random
trial
demonstr
efficaci
poc
medic
research
council
adjuv
gastric
infusion
chemotherapi
magic
trial
evalu
poc
ecf
regimen
os
resect
stomach
adenocarcinoma
patient
report
increas
os
poc
surviv
rate
versu
hr
death
p
pf
hr
progress
death
p
cunningham
et
al
n
engl
j
med
trial
conduct
resect
lower
case
gc
case
random
receiv
preoper
chemotherapi
cycl
monthlu
regimen
follow
surgeri
n
postop
chemotherapi
n
poc
result
better
os
vs
death
hr
p
df
versu
hr
p
multivari
analysi
poc
p
distal
site
gc
p
independ
prognost
factor
resect
rate
improv
vs
p
toxic
manag
observ
patient
without
increas
postop
morbid
boig
v
et
al
ascoabstract
jco
submit
public
eortc
trial
report
increas
resect
preoper
chemotherapi
recent
posit
os
ronellenfitsch
u
et
al
jco
conclus
case
potenti
resect
poc
must
consid
significantli
increas
chanc
get
cur
resect
better
df
os
futur
better
toler
effici
chemotherapi
test
biolog
test
trial
tratuzumab
posit
well
differ
combin
crt
thursday
novemb
erato
c
meet
expert
gastroenteropancreat
neuroendocrin
tumour
bertram
wiedenmann
neuroendocrin
tumor
net
gastroenteropancreat
system
significantli
increas
past
decad
current
incid
approx
preval
similar
gastric
carcinoma
modlin
et
al
like
caus
improv
awar
among
doctor
better
diagnost
modal
improv
also
advanc
imag
modal
doubl
balloon
enteroscopi
mr
sellink
capsul
endoscopi
etc
caus
may
also
relat
environment
dietari
factor
similar
adenocarcinoma
net
subdivid
accord
primari
tumor
locat
histolog
state
differenti
tumor
extent
hormon
activityfunction
latter
observ
less
half
case
natur
cours
excess
releas
hypersecret
peptid
biogen
amin
differ
consider
primari
exampl
pancreat
primari
character
faster
tumor
progress
hypersecret
peptid
hormon
gastrin
insulin
vip
wherea
ileal
net
slower
grow
show
hypersecret
biogen
amin
approx
half
case
lead
carcinoid
syndrom
order
categor
also
treat
net
better
past
new
tnm
classif
propos
european
neuroendocrin
tumor
societi
enet
includ
grade
system
rindi
et
al
number
center
alreadi
demonstr
new
tnm
classif
applic
daili
routin
eg
pape
et
al
recent
year
impress
spectrum
treatment
option
evolv
esp
pancreat
net
current
treatment
includ
new
biolog
small
molecul
mtor
inhibitor
everolimu
tki
sunitinib
shown
efficaci
esp
case
pancreat
primari
tumor
grade
kulk
et
al
yao
et
al
addit
novel
oral
avail
chemotherapeut
temozolomid
capecitabin
shown
efficaci
pancreat
net
kulk
et
al
furthermor
folfox
also
lead
poorli
differenti
net
remiss
well
prolong
time
tumor
progress
pape
et
al
biotherapeut
somatostatin
analogu
ssa
esp
octreotid
gain
renew
attent
base
newli
demonstr
antiprolif
action
midgut
tumor
rink
et
al
addit
new
ssa
pasireotid
shown
control
carcinoid
syndrom
patient
refractori
convent
therapi
octreotid
lanreotid
depot
furthermor
therapeut
advanc
also
observ
radiolabel
ssa
coupl
yttrium
lutetium
latter
radionuclid
lead
ttp
month
kwekkeboom
et
al
final
new
abl
therapeut
procedur
use
exampl
select
intern
radiat
therapi
sirt
combin
radiol
microspher
seem
also
promis
though
valid
data
still
lack
summari
smaller
monocentr
well
sever
multicentr
prospect
trial
shown
treatment
net
consider
improv
aim
present
summar
exist
data
present
treatment
algorithm
accord
variou
primari
function
net
thursday
novemb
erato
c
meet
expert
gastrointestin
lymphoma
finbarr
e
cotter
thursday
novemb
terpsichor
b
educ
symposium
renal
cell
carcinoma
aristot
bamia
immunotherapi
consist
ifna
long
standard
care
advanc
renal
cell
carcinoma
rcc
therapi
especi
associ
consider
toxic
minor
patient
experi
benefit
approach
specif
long
establish
patient
achiev
complet
respons
usual
maintain
mani
year
render
patient
cure
diseas
patient
undergon
nephrectomi
low
volum
lung
metastas
excel
outcom
patient
make
treatment
toler
still
reason
option
initi
manag
experi
ifna
wider
due
favor
toxic
profil
patient
belong
low
risk
group
accord
mskcc
stratif
median
surviv
around
year
cure
achiev
ifna
sinc
novel
therapi
achiev
superior
result
compar
ifna
even
favor
prognosi
group
agent
consid
standard
diseas
treatment
paradigm
advanc
rcc
chang
last
year
understand
import
angiogenesi
carcinogenesi
well
progress
renal
cancer
led
develop
target
therapi
vascular
endotheli
growth
factor
vegf
receptor
drug
act
via
either
direct
inhibit
circul
vegf
bevacizumab
inhibit
multipl
tyrosin
kinas
includ
receptor
vegf
angiogen
factor
sorafenib
sunitinib
pazopanib
addit
inhibitor
mammalian
target
rapamycin
mtor
pathway
temsirolimu
everolimu
indirectli
stimul
angiogenesi
also
shown
activ
certain
group
patient
advanc
rcc
role
immunotherapi
therefor
within
context
chang
standard
advanc
rcc
current
combin
immunotherapi
target
therapi
appear
promis
strategi
incorpor
immunotherapi
contemporari
treatment
guidelin
ifna
use
combin
bevacizumab
treatment
follow
result
two
random
studi
show
signific
prolong
pf
compar
ifna
alon
result
studi
suggest
synergist
effect
ifna
therapi
also
studi
combin
bevacizumab
combin
associ
higher
toxic
gener
safe
although
dose
reduct
may
necessari
phase
ii
studi
combin
result
rr
median
pf
month
median
os
month
random
studi
combin
sorafenib
feasibl
overal
benefit
combin
compar
sorafenib
alon
conclus
role
immunotherapi
era
target
therapi
still
evolv
although
minor
patient
may
still
benefit
upfront
combin
novel
antiangiogen
agent
seem
promis
way
still
wide
use
immunotherapi
diseas
thursday
novemb
terpsichor
b
educ
symposium
renal
cell
carcinoma
axel
bex
target
agent
rcc
improv
outcom
metastat
patient
increas
interest
multimod
approach
integr
efficaci
safeti
drug
combin
surgeri
earli
advanc
diseas
encourag
respons
observ
primari
tumour
metastas
may
lead
chang
role
sequenc
surgeri
treatment
rcc
cytoreduct
nephrectomi
cn
shown
improv
overal
surviv
patient
metastat
rcc
treat
combin
target
therapi
cn
metastat
set
potenti
improv
efficaci
toler
rel
cytokin
therapi
prospect
studi
underway
present
definit
evid
support
chang
current
treatment
paradigm
absenc
prospect
random
data
cn
remain
part
treatment
algorithm
patient
metastat
diseas
favour
intermedi
prognosi
good
perform
resect
tumour
view
larg
base
two
random
studi
demonstr
cn
associ
surviv
advantag
select
mrcc
patient
treat
contrast
patient
poor
perform
larg
metastat
burden
highli
aggress
subtyp
sarcomatoid
featur
unlik
benefit
cn
may
better
system
therapi
first
two
phase
iii
random
studi
open
accrual
address
respect
question
role
time
nephrectomi
carmena
trial
phase
iii
random
studi
compar
nephrectomi
plu
sunitinib
versu
sunitinib
without
nephrectomi
metastat
rcc
primari
end
point
overal
surviv
rather
investig
indiscrimin
whether
cn
benefit
anoth
approach
identifi
individu
cn
alter
natur
cours
mrcc
identif
would
requir
understand
new
clinic
molecular
predictor
therefor
rational
trial
presurg
target
therapi
investig
pretreat
primari
tumour
tissu
eortc
trial
random
phase
iii
trial
compar
sunitinib
follow
nephrectomi
case
metastas
follow
sunitinib
versu
nephrectomi
follow
sunitinib
patient
synchron
metastat
renal
cell
carcinoma
primari
endpoint
progress
free
surviv
addit
cn
increas
evid
suggest
presurg
target
therapi
may
role
metastasectomi
select
respond
reduc
extent
prior
resect
patient
diseas
larg
advanc
primari
tumour
use
target
agent
downsiz
tumour
investig
howev
degre
primari
tumour
shrinkag
rate
surgic
relev
seen
current
gener
agent
suffici
high
justifi
regular
use
final
toler
safeti
target
agent
use
must
consid
particularli
adjuv
set
therapi
prevent
recurr
metastasi
current
investig
friday
novemb
terpsichor
b
current
issu
oncolog
optim
select
patient
surgeri
advanc
surgeri
john
davi
evalu
man
newli
diagnos
clinic
local
prostat
cancer
begin
question
whether
patient
best
suit
immedi
cur
therapi
versu
activ
surveil
absenc
better
screen
tool
serum
psa
screen
result
larg
fraction
men
diagnos
earli
cancer
like
polici
immedi
therapi
activ
surveil
perfect
strategi
current
literatur
indic
upward
men
earli
diseas
manag
surveil
provid
will
undergo
repeat
evalu
delay
therapi
evid
increas
risk
men
higher
volum
tumor
intermedi
high
grade
find
patient
counsel
regard
standard
cur
therapi
surgeri
radiat
possibl
altern
treatment
cryotherapi
ultrasound
etc
comparison
surgeri
radiat
done
use
american
urolog
associ
andor
european
associ
urolog
guidelin
offer
art
review
level
evid
point
point
review
oncolog
function
outcom
surgeon
point
advantag
surgeri
includ
patholog
stage
opportun
radiat
simplifi
monitor
perhap
greater
understand
year
durabl
cure
discuss
qualiti
life
includ
known
trend
sexual
urinari
bowel
side
effect
one
therapi
shown
superior
unit
state
grow
number
worldwid
center
select
surgeri
may
includ
whether
robot
approach
util
strong
trend
observ
physician
referr
high
volum
surgeon
literatur
open
surgeri
demonstr
clear
improv
outcom
train
volum
perform
robot
surgeri
similar
clear
evid
benefit
robot
approach
includ
lower
blood
loss
shorter
hospit
stay
fewer
complic
fewer
urinari
strictur
oncolog
function
outcom
well
studi
like
influenc
surgeon
experi
tool
select
current
high
volum
surgeon
abl
present
prospect
patient
program
adapt
approach
improv
outcom
includ
reduc
posit
margin
improv
select
imag
nomogram
improv
urinari
control
reduc
complic
select
patient
extend
pelvic
lymph
node
dissect
furthermor
result
surgic
train
quantifi
surgic
simul
develop
ultim
optim
outcom
achiev
open
robot
approach
howev
latter
approach
seem
promis
regard
reduc
wide
variat
result
demonstr
open
surgeri
high
volum
surgeon
abl
adapt
techniqu
almost
situat
although
recent
trend
util
drug
elut
stent
mandat
morbid
obes
remain
possibl
contraind
friday
novemb
erato
ab
lectur
state
art
manag
testicular
tumour
alan
horwich
germ
cell
cancer
highli
curabl
occur
young
adult
risk
long
term
treatment
toxic
import
consid
option
manag
seminoma
non
seminoma
pathognom
chromosom
signatur
isochromosom
immunohistochem
analys
aid
diagnosi
stain
afp
hcg
plap
tumour
usual
aris
non
invas
carcinoma
situ
lesion
malign
common
histori
testicular
maldesc
testi
atroph
genet
compon
aetiolog
cancer
common
brother
case
gener
popul
male
analysi
level
alphafetoprotein
afp
human
chorion
gonadotrophin
hcg
blood
help
diagnosi
prognosi
monitor
lactat
dehydrogenas
also
tumour
marker
use
prognost
stage
seminoma
tradit
treat
adjuv
radiotherapi
abdomin
pelvic
lymph
node
polici
recosid
sinc
either
surveil
adjuv
carboplatin
like
lower
risk
caus
second
cancer
stage
manag
orchidectomi
surveil
seem
pet
aid
specif
stage
adjuv
chemotherapi
effect
altern
singl
cycl
reduc
recurr
risk
less
metastat
germ
cell
tumour
classifi
use
intern
agre
system
good
prognosi
estim
year
surviv
defin
non
seminoma
low
marker
poor
prognosi
year
surviv
high
marker
non
pulmonari
viscer
metastas
mediastin
primari
site
intermedi
prognosi
year
surviv
seminoma
good
prognosi
unless
viscer
metastas
year
surviv
vs
intermedi
prognosi
good
prognosi
patient
treat
cycl
bep
chemotherapi
bleomycin
etoposid
cisplatinum
intermedi
prognosi
treat
cycl
bep
chemotherapi
poor
prognosi
either
cycl
bep
investig
usual
protocol
residu
mass
common
chemotherapi
bulki
seminoma
neg
pet
scan
reassur
howev
fals
posit
scan
uncommon
presum
due
macrophag
activ
follow
chemotherapi
consider
given
resect
residu
mass
case
contain
activ
malign
matur
teratoma
subject
late
malign
chang
left
patient
best
evalu
within
multidisciplinari
team
patient
relaps
first
line
bep
chemotherapi
still
cure
approxim
case
chemotherapi
regimen
incorpor
paclitaxel
ifosfamid
usual
platinum
drug
import
incorpor
resect
residu
mass
multidisciplinari
approach
recommend
role
high
dose
chemotherapi
salvag
remain
unproven
though
good
result
report
retrospect
seri
includ
two
three
high
dose
cycl
friday
novemb
terpsichor
b
current
issu
oncolog
challeng
prostat
cancer
part
ii
optim
applic
therapi
patient
localis
prostat
cancer
deborah
kuban
thursday
novemb
terpsichor
b
educ
symposium
renal
cell
carcinoma
athena
matakid
kidney
cancer
account
adult
cancer
incid
increas
western
countri
despit
recent
advanc
understand
underli
biolog
process
develop
new
therapeut
approach
associ
mortal
remain
high
renal
cell
carcinoma
rcc
aris
renal
tubular
epitheli
cell
account
kidney
tumour
case
sporad
rcc
clear
cell
histolog
follow
papillari
chromophob
oncocytoma
collect
duct
carcinoma
molecular
effort
rcc
research
focus
upon
sever
hereditari
syndrom
predispos
diseas
includ
von
hereditari
papillari
renal
carcinoma
hereditari
leiomyomatosi
tuber
sclerosi
complex
somat
mutat
gene
associ
syndrom
vhl
bhd
fh
respect
identifi
sporad
rcc
inde
defect
vhl
gene
appear
respons
case
sporad
rcc
studi
cellular
consequ
specif
genet
mutat
associ
hereditari
rcc
spawn
much
current
understand
tumourigenesi
renal
tubular
epithelia
howev
well
studi
genet
event
account
total
sporad
tumourigenesi
rcc
suggest
addit
caus
mutat
remain
unidentifi
studi
rcc
pathogenesi
limit
pauciti
genet
defin
anim
model
mice
genet
disrupt
vhl
fh
develop
kidney
tumour
similarli
combin
condit
inactiv
vhl
pten
tumour
suppressor
gene
mous
kidney
elicit
cyst
format
reminisc
human
vhl
phenotyp
overt
neoplasia
date
mutat
bhd
apc
tumour
suppressor
gene
yield
tumour
reminisc
rcc
genet
engin
anim
howev
mutat
gene
rare
sporad
rcc
anim
model
provid
accur
pictur
divers
molecular
mechan
implic
diseas
moreov
none
model
ideal
studi
renal
tumorigenesi
owe
high
neonat
mortal
bhd
apc
long
latenc
tumour
develop
lack
target
addit
improv
anim
model
rcc
offer
prospect
advanc
basic
preclin
studi
renal
epitheli
neoplasia
recent
new
form
somat
mutagenesi
forward
genet
develop
gener
novel
tumour
model
instantan
identifi
causal
loci
method
provid
unbias
approach
gener
novel
model
rcc
identif
caus
gene
psa
screen
consequ
friday
novemb
erato
c
debat
challeng
prostat
cancer
part
perspect
cancer
uniqu
diseas
special
challeng
kurt
miller
two
random
screen
studi
publish
andriol
crawford
et
al
schroder
hugosson
et
al
sever
flaw
make
difficult
assess
result
plco
trial
erspc
studi
suggest
signific
reduct
prostat
cancer
specif
mortal
psa
test
appli
earli
detect
one
problem
still
high
number
need
screen
treat
howev
recent
report
suggest
number
decreas
substanti
longer
avail
hugosson
carlsson
et
al
relev
problem
howev
psa
screen
lead
dramat
overdetect
clinic
insignific
prostat
cancer
earlier
calcul
erspc
studi
suggest
overdetect
rate
close
draisma
boer
et
al
overdetect
per
se
irrelev
result
overtreat
henc
one
consequ
data
introduc
activ
surveil
one
standard
approach
low
risk
screen
detect
prostat
cancer
midterm
data
studi
suggest
excel
prostat
cancer
specif
surviv
rate
klotz
van
den
bergh
roemel
et
al
hand
inher
risk
underestim
tumor
inform
set
biopsi
psa
dre
current
avail
suardi
capitanio
et
al
narrow
path
exist
overtreat
underestim
reflect
psycholog
burden
activ
surveil
one
side
versu
potenti
morbid
radic
treatment
side
daili
practic
often
lead
rather
choos
radic
treatment
activ
surveil
thu
avoid
lengthi
burdensom
discuss
patient
oncolog
set
overtreat
uncommon
feel
better
undertreat
potenti
life
threaten
hazard
current
solut
dilemma
focal
therapi
provid
lower
morbid
profil
still
infanc
recommend
routin
clinic
use
hand
activ
surveil
suspici
psa
valu
without
enforc
diagnosi
biopsi
may
take
psycholog
burden
patient
intrins
disadvantag
establish
diagnosi
prostat
cancer
unmet
need
provid
accur
prognosi
individu
patient
often
stress
littl
progress
actual
made
last
year
molecular
maker
like
seem
provid
increment
progress
dera
aubin
et
al
work
progress
schostak
schwall
et
al
sreekumar
poisson
et
al
immedi
futur
howev
dilemma
stay
need
seek
best
choic
individu
patient
limit
inform
avail
refer
andriol
g
l
e
crawford
et
al
mortal
result
random
screen
trial
n
engl
j
med
dera
l
aubin
et
al
molecular
urin
assay
predict
prostat
biopsi
outcom
j
urol
draisma
g
r
boer
et
al
lead
time
overdetect
due
antigen
screen
estim
european
random
studi
screen
prostat
cancer
j
natl
cancer
inst
hugosson
j
carlsson
et
al
mortal
result
goteborg
randomis
screen
trial
lancet
oncol
klotz
l
activ
surveil
favor
risk
prostat
cancer
rational
risk
result
urol
oncol
schostak
g
p
schwall
et
al
annexin
urin
highli
specif
noninvas
marker
prostat
cancer
earli
detect
j
urol
schroder
f
h
j
hugosson
et
al
screen
mortal
random
european
studi
n
engl
j
med
sreekumar
l
poisson
et
al
metabolom
profil
delin
potenti
role
sarcosin
prostat
cancer
progress
natur
suardi
n
u
capitanio
et
al
current
use
criteria
activ
surveil
men
prostat
cancer
analysi
patholog
featur
cancer
van
den
bergh
r
c
roemel
et
al
outcom
men
prostat
cancer
elig
activ
surveil
manag
expectantli
eur
urol
perspect
screen
prostat
find
optim
applic
screen
test
friday
novemb
erato
c
debat
challeng
prostat
cancer
part
perspect
screen
prostat
cancer
uniqu
diseas
special
challeng
fritz
h
screen
prostat
cancer
save
live
shown
european
random
studi
screen
prostat
cancer
erspc
public
gothenburg
screen
trial
partner
erspc
howev
uncertainti
downsid
screen
uncertainti
includ
number
need
screen
number
need
treat
achiev
longer
set
erspc
studi
independ
problem
overdiagnosi
overtreat
result
present
screen
algorithm
antigen
psa
antigen
prostat
specif
prostat
cancer
specif
result
overlap
increas
serum
psa
due
benign
enlarg
carcinoma
prostat
specif
critic
psa
rang
ngml
biopsi
indic
earli
diagnosi
achiev
dilemma
yet
resolv
erspc
studi
interim
result
erspc
studi
report
analysi
base
men
age
screen
interv
use
studi
show
year
reduct
prostat
cancer
mortal
favor
screen
adjust
contamin
mortal
reduct
men
fact
screen
number
need
screen
amount
number
need
treat
find
consid
main
downsid
togeth
larg
amount
overdiagnosi
gothenburg
screen
trial
gothenburg
screen
trial
initi
independ
erspc
join
erspc
partner
shortli
thereaft
studi
report
absolut
reduct
prostat
cancer
mortal
year
rel
reduct
prostat
cancer
mortal
amount
intent
screen
analysi
fact
screen
consid
year
number
need
invit
screen
decreas
number
need
treat
accept
overdiagnosi
overtreat
alreadi
mention
problem
overdiagnosi
overtreat
independ
eventu
achiev
low
number
need
screen
number
need
treat
task
urolog
profess
work
develop
methodolog
decreas
overdiagnosi
obvious
new
marker
replac
psa
would
desir
conclus
question
anymor
screen
reduc
prostat
cancer
mortal
overdiagnosi
overtreat
decreas
screen
less
aggress
select
men
wish
undergo
earli
diagnosi
refus
introduct
popul
screen
health
polici
depend
improv
side
screen
mainli
reduct
overdiagnosi
overtreat
fh
hugosson
j
roobol
mj
tammela
tlj
ciatto
nelen
v
kwiatkowski
lujan
lilja
h
zappa
deni
lj
recker
f
berengu
l
bangma
ch
au
g
viller
rebillard
x
van
der
kwast
th
blijenberg
bg
moss
sm
de
kone
hj
auvinen
erspc
investig
screen
mortal
random
european
studi
n
engl
j
med
mar
mj
kerkhof
fh
cuzick
j
sasieni
p
hakama
stenman
uh
ciatto
nelen
v
kwiatkowski
lujan
lilja
h
zappa
deni
l
recker
f
berengu
ruutu
kujala
p
bangma
ch
au
g
tammela
tl
viller
rebillard
x
moss
sm
de
kone
hj
hugosson
j
auvinen
prostat
cancer
mortal
reduct
screen
adjust
nonattend
contamin
european
randomis
studi
screen
prostat
cancer
erspc
eur
urol
oct
j
carlsson
au
g
bergdahl
khatami
lod
p
pihl
cg
strann
j
holmberg
e
lilja
h
mortal
result
random
screen
trial
lancet
oncol
aug
friday
novemb
erato
ab
debat
intraperiton
chemotherapi
ovarian
cancer
deborah
armstrong
cumul
bodi
evid
multipl
random
trial
ip
vs
iv
studi
indic
averag
effect
ip
therapi
reduc
death
rate
approxim
conclus
nci
overview
ip
therapi
cochran
overview
studi
also
show
increas
toxic
decreas
qualiti
life
treatment
measur
larg
equal
treatment
complet
ip
therapi
gog
produc
longest
surviv
report
date
random
phase
iii
trial
advanc
ovarian
cancer
yet
therapi
gain
widespread
accept
argu
benefit
treatment
given
gog
due
differ
dose
intens
regimen
ip
regimen
design
provid
intens
therapi
deliv
iv
thu
argument
differ
dose
agent
use
iv
ip
arm
circuit
argument
abil
give
higher
frequent
dose
use
ip
rout
one
benefit
ip
therapi
deliv
use
iv
rout
toxic
greater
ip
arm
increas
toxic
death
qualiti
life
measur
similar
iv
ip
arm
one
year
therapi
complet
less
toxic
therapi
inde
prefer
clinic
outcom
equal
howev
benefit
seen
ip
therapi
gog
import
advanc
equival
recent
studi
shown
contemporari
support
care
measur
experienc
dedic
treatment
team
major
patient
complet
ip
therapi
furthermor
modif
ip
chemotherapi
regimen
significantli
improv
toler
eas
administr
critic
also
suggest
two
possibl
explan
improv
overal
surviv
patient
relaps
ip
therapi
live
longer
natur
treatment
alter
biolog
diseas
abl
receiv
effect
treatment
treatment
provid
either
benefici
outcom
desir
howev
two
addit
potenti
explan
improv
surviv
one
patient
relaps
later
like
sensit
second
line
treatment
patient
would
relaps
iv
therapi
prevent
relaps
ie
cure
use
ip
therapi
thursday
novemb
erato
c
meet
expert
role
consolid
mainten
therapi
ovarian
cancer
jonathan
ledermann
ovarian
cancer
one
chemosensit
solid
malign
advanc
tumour
respond
chemotherapi
patient
widespread
diseas
expect
complet
clinic
remiss
follow
surgeri
chemotherapi
usual
carboplatin
paclitaxel
regimen
remain
standard
care
decad
despit
attempt
improv
outcom
ad
third
fourth
agent
durat
remiss
regimen
remain
remark
constant
median
surviv
rate
month
residu
microscop
diseas
resist
drug
key
issu
affect
surviv
ovarian
cancer
patient
remiss
mainten
therapi
investig
attempt
erad
residu
diseas
suppress
growth
first
question
address
whether
chemotherapi
given
longer
would
extend
surviv
randomis
trial
mainten
consolid
cours
paclitaxel
topotecan
produc
mix
result
paclitaxel
shown
prolong
surviv
result
need
interpret
context
overal
surviv
nevertheless
new
ongo
trial
investig
less
toxic
taxan
analogu
altern
strategi
use
novel
molecular
target
drug
consolid
remiss
randomis
phase
ii
evalu
design
develop
screen
sever
agent
might
use
studi
one
drug
bibf
tripl
angiokinas
inhibitor
identifi
activ
compound
ovarian
cancer
trial
perform
use
drug
therapi
combin
carboplatin
paclitaxel
mainten
therapi
drug
appear
promis
group
agent
ovarian
cancer
angiogenesi
play
key
role
growth
progress
ovarian
cancer
studi
bevacizumab
monoclon
antibodi
target
circul
vegf
shown
good
singl
agent
activ
recurr
ovarian
cancer
prolong
surviv
two
intern
studi
chemotherapi
combin
bevacizumab
follow
mainten
therapi
antibodi
complet
first
gog
present
asco
show
signific
prolong
surviv
patient
receiv
month
therapi
bevacizumab
result
similar
studi
icon
present
autumn
result
avail
discuss
third
trial
mainten
therapi
pazopanib
small
molecul
multikinas
inhibitor
follow
carboplatin
paclitaxel
complet
recruit
result
yet
avail
studi
icon
cediranib
vegfr
tyrosin
kinas
inhibitor
perform
relaps
ovarian
cancer
result
gog
clearli
demonstr
import
therapi
ovarian
cancer
indic
mainten
therapi
like
best
strategi
howev
critic
interpret
result
need
order
understand
use
therapi
effect
improv
outcom
ovarian
cancer
friday
novemb
erato
ab
debat
intraperiton
chemotherapi
ovarian
cancer
eric
professor
head
medic
oncolog
depart
franc
past
year
sever
phase
iii
trial
conduct
compar
iv
chemotherapi
combin
administr
treatment
patient
minim
residu
diseas
initi
surgeri
largest
one
run
us
confirm
superior
regimen
includ
ip
deliveri
chemotherapi
systemat
review
trial
includ
patient
perform
cochran
collabor
show
women
receiv
intraperiton
chemotherapi
experi
signific
reduct
risk
progress
death
hr
respect
howev
despit
magnitud
surviv
improv
ip
treatment
rare
part
standard
therapi
routin
practic
part
sceptic
relat
fact
trial
control
arm
time
studi
conduct
longer
standard
care
time
put
result
routin
daili
practic
moreov
posit
result
ip
trial
exceedingli
public
includ
nci
clinic
announc
view
magnitud
benefit
observ
instanc
benefit
pf
ip
arm
compar
iv
last
publish
ip
trial
borderlin
signific
p
puzzl
fact
larg
posit
trial
complex
design
assess
multipl
factor
addit
ip
treatment
one
swog
rout
administr
sole
variabl
experiment
control
arm
trial
shown
signific
advantag
benefitrisk
ratio
cisplatinumvia
ip
rout
data
support
biolog
pharmacokinet
rational
direct
instil
cisplatinum
site
diseas
gener
confin
convinc
data
carboplatin
paclitaxel
doublet
use
standard
therapi
ovarian
cancer
addit
scientif
concern
ip
therapi
gener
associ
higher
complic
includ
cathet
complic
obstruct
infect
bowel
perfor
fistula
format
nausea
abdomin
discomfort
pain
relat
infus
fluid
chemotherapi
abdomen
metabol
imbal
neurotox
due
higher
drug
absorpt
peritoneum
gog
trial
nearli
half
patient
unabl
complet
cycl
whole
program
ip
therapi
temptat
exist
modifi
design
ip
regimen
previous
describ
order
overcom
toxic
use
carboplatin
instead
cisplatinum
alter
dose
schedul
drug
chang
need
test
phase
iii
trial
could
affect
surviv
advantag
conclus
year
inclus
first
patient
ip
trial
ip
chemotherapi
remain
option
optim
debulk
patient
without
convinc
advantag
benefitrisk
ratio
iv
therapi
time
biolog
target
therapi
offer
new
prospect
advanc
treatment
cancer
includ
ovarian
cancer
question
rais
opportun
devot
signific
part
energet
financi
resourc
gyn
commun
launch
sever
new
ip
trial
ovarian
cancer
thursday
novemb
terpsichor
keynot
lectur
multidisciplinari
natur
cancer
care
j
gordon
mcvie
friday
novemb
terpsichor
educ
symposium
lung
cancer
non
small
cell
lung
cancer
michael
cullen
tradit
mainten
treatment
oncolog
refer
continu
system
therapi
patient
respond
remiss
induct
aim
prolong
remiss
within
broad
definit
least
scenario
quit
differ
implic
concern
mechan
action
mainten
therapi
first
scenario
agent
agent
use
induct
henc
presum
contribut
respons
continu
hope
tumour
retain
sensit
second
scenario
agent
use
remiss
induct
commenc
complet
induct
therapi
hope
expos
tumour
differ
agent
agent
prolong
remiss
perhap
resist
scenario
might
call
earli
second
line
therapi
distinct
import
patient
advanc
cell
lung
cancer
nsclc
deterior
rapidli
cancer
comorbid
prevent
ever
receiv
therapi
one
might
anticip
benefit
earli
administr
line
therapi
remiss
mainten
rather
wait
progress
support
hypothesi
come
data
show
around
fewer
patient
clinic
trial
ever
receiv
line
therapi
furthermor
trial
compar
immedi
delay
line
docetaxel
report
benefit
immedi
use
drug
recent
weight
evid
support
discontinu
chemotherapi
advanc
nsclc
cycl
induct
therapi
addit
recent
year
agent
without
seriou
cumul
toxic
becom
avail
realist
mainten
agent
discontinu
induct
allow
patient
limit
life
expect
treatment
holiday
howev
renew
interest
concept
mainten
trial
pemetrex
erlotinib
agent
given
long
period
without
seriou
cumul
toxic
patient
trial
shown
signific
extens
progress
free
surviv
placebo
control
trial
case
pemetrex
statist
signific
prolong
overal
surviv
nsclc
report
case
receiv
pemetrex
induct
therapi
treatment
well
toler
effect
may
reflect
earli
administr
activ
second
line
agent
remain
seen
whether
similar
benefit
accru
patient
pemetrex
induct
therapi
trial
current
underway
test
final
retrospect
analysi
trial
test
mainten
erlotinib
pemetrex
demonstr
benefit
accru
case
stabl
diseas
induct
achiev
partial
complet
remiss
appar
observ
need
test
prospect
explain
biolog
learn
role
mainten
therapi
advanc
nsclc
friday
novemb
terpsichor
educ
symposium
lung
cancer
non
small
cell
lung
cancer
thierri
le
chevali
cell
lung
cancer
mostli
includ
squamou
cell
carcinoma
adenocarcinoma
larg
cell
carcinoma
three
subtyp
repres
lung
tumor
lead
caus
death
cancer
world
median
age
diagnosi
year
western
countri
two
third
patient
present
local
advanc
metastat
diseas
around
initi
limit
diseas
eventu
fail
distantli
vast
major
nsclc
patient
potenti
candid
palli
system
treatment
cours
diseas
individu
publish
establish
superior
chemotherapi
support
care
patient
advanc
nsclc
result
recent
updat
confirm
patient
trial
overal
surviv
benefit
year
chemotherapi
also
improv
qualiti
life
control
symptom
patient
good
perform
statu
classic
recommend
use
platin
compoud
combin
third
gener
agent
includ
vinorelbin
gemcitabin
taxan
pemetrex
nsclc
integr
palli
care
earli
stage
treatment
also
prolong
surviv
improv
qualiti
life
addit
antiangiogen
monoclon
antibodi
bevacizumab
antiegfr
monoclon
antibodi
cetuximab
standard
platin
base
chemotherapi
may
prolong
surviv
case
select
patient
remain
unclear
present
predict
test
guid
therapeut
decis
second
line
chemotherapi
docetaxel
pemetrex
also
show
activ
even
benefit
overal
surviv
remain
modest
use
biolog
marker
thymidil
synthas
yet
proven
efficaci
choic
cytotox
agent
addit
target
tki
standard
chemotherapi
disappoint
never
show
superior
tover
chemotherapi
alon
gener
popul
recent
year
sever
target
identifi
particularli
among
grow
popul
adenocarcinoma
sever
target
agent
develop
second
line
singl
agent
combin
specif
drug
larg
chemona
popul
demonstr
patient
mutat
exon
use
first
line
egfr
tki
offer
better
outcom
compar
classic
cytotox
chemotherapi
recent
report
inhibit
alk
might
also
impact
surviv
select
patient
adenocarcinoma
conclus
chemotherapi
remain
standard
treatment
patient
advanc
nsclc
addit
antiangiogen
monoclon
antibodi
prolong
surviv
case
substitut
target
agent
cytotox
chemotherapi
may
appropri
select
patient
constitut
major
challeng
come
decad
friday
novemb
terpsichor
educ
symposium
lung
cancer
small
cell
lung
cancer
eric
lim
combin
modal
therapi
use
chemotherapi
thorac
irradi
current
standard
care
small
cell
lung
carcinoma
long
term
result
poor
cumul
result
year
north
american
trial
report
current
median
surviv
data
surveil
epidemiolog
end
result
seer
programm
nation
cancer
institut
bethesda
maryland
usa
report
overal
year
surviv
previou
major
randomis
trial
surgeri
small
cell
lung
cancer
perform
era
prior
pet
clinic
stage
preoper
select
base
either
plain
chest
ct
part
account
high
proport
exploratori
thoracotomi
inclus
patient
current
accept
suitabl
surgeri
light
publish
evid
surgeri
small
cell
lung
cancer
establish
treatment
modal
current
surgic
seri
howev
report
excel
surviv
select
patient
lung
cancer
royal
brompton
hospit
associ
diseas
free
surviv
similar
result
achiev
multimod
treatment
includ
surgeri
eberhardt
et
al
year
overal
surviv
surviv
toronto
howev
avail
evid
prognosi
similar
group
patient
treat
current
standard
concurr
view
current
data
surgeri
featur
promin
part
multimod
manag
british
guidelin
advoc
broader
remit
consider
surgeri
patient
small
cell
lung
refer
pa
freidlin
b
saxman
johnson
dh
livingston
rb
shepherd
fa
johnson
year
clinic
research
patient
small
cell
lung
carcinoma
north
america
cancer
r
page
n
morgensztern
read
w
tierney
r
vlahioti
spitznagel
el
piccirillo
j
chang
epidemiolog
lung
cancer
unit
state
last
year
analysi
surveil
epidemiolog
end
result
databas
j
clin
oncol
w
scad
jg
medic
research
council
compar
trial
surgeri
radiotherapi
primari
treatment
carcinoma
bronchu
lancet
piantadosi
thoma
p
payn
ruckdeschel
j
giaccon
g
prospect
random
trial
determin
benefit
surgic
resect
residu
diseas
follow
respons
small
cell
lung
cancer
combin
chemotherapi
chest
suppl
e
goldstraw
p
surgeri
lung
cancer
time
j
clin
oncol
w
stamati
g
stuschk
wilk
h
muller
mr
kolk
flasshov
schutt
j
stahl
schlenger
l
budach
v
greschuchna
stuben
g
teschler
h
sack
h
seeber
prognost
orient
multimod
treatment
includ
surgeri
select
patient
lung
cancer
patient
stage
ib
iiib
result
phase
ii
trial
br
j
cancer
fa
ginsberg
rj
feld
r
evan
wk
johansen
e
surgic
treatment
limit
lung
cancer
univers
toronto
lung
oncolog
group
experi
j
thorac
cardiovasc
surg
kim
k
blum
r
saus
wt
livingston
rb
komaki
r
wagner
h
aisner
johnson
dh
compar
thorac
radiotherapi
limit
lung
cancer
treat
concurr
cisplatin
etoposid
n
engl
j
med
e
baldwin
beckl
duffi
j
entwisl
j
c
kerr
k
macfi
mcguigan
j
padley
popat
screaton
n
snee
waller
warburton
c
win
guidelin
radic
manag
patient
lung
cancer
thorax
press
friday
novemb
terpsichor
educ
symposium
lung
cancer
small
cell
lung
cancer
paul
lorigan
outcom
patient
lung
cancer
remain
poor
advanc
treatment
kept
pace
seen
cancer
main
improv
outcom
relat
use
radiotherapi
though
chemotherapi
remain
cornerston
treatment
major
patient
chemotherapi
regimen
standard
care
base
data
systemat
review
howev
recent
cochran
review
randomis
control
trial
report
signific
surviv
benefit
platinum
base
treatment
month
unclear
whether
cisplatin
carboplatin
use
interchang
studi
address
power
equival
combin
modal
treatment
chemotherapi
earli
concurr
radiotherapi
remain
standard
care
patient
limit
stage
diseas
base
number
randomis
control
trial
systemat
review
new
drug
would
almost
certainli
need
deliver
concurr
radiotherapi
make
signific
impact
limit
stage
diseas
role
mainten
chemotherapi
remain
unclear
concern
toxic
howev
randomis
studi
encompass
patient
report
surviv
benefit
year
patient
extens
stage
edsclc
diseas
good
perform
statu
cycl
platinum
base
chemotherapi
standard
care
clear
benefit
ad
third
fourth
drug
standard
treatment
altern
treatment
strategi
evalu
new
agent
edsclc
usual
involv
either
addit
new
drug
combin
substitut
etoposid
clear
benefit
combin
platinum
topotecan
first
line
treatment
thought
topotecan
drug
licens
second
line
therapi
show
clear
benefit
qualiti
life
surviv
best
support
care
two
studi
evalu
addit
paclitaxel
report
increas
toxic
surviv
benefit
combin
found
inferior
larg
phase
studi
close
earli
data
safeti
monitor
committe
median
overal
surviv
month
month
irinotecan
shown
activ
asian
popul
patient
benefit
seen
larg
phase
studi
carri
swog
recent
report
inferior
amrubicin
synthet
anthracyclin
shown
signific
activ
set
sensit
resistantrefractori
patient
recent
first
line
randomis
phase
ii
studi
show
respons
rate
versu
larg
phase
iii
studi
set
compar
amrubicin
topotecan
complet
accrual
result
impact
futur
studi
design
set
chemotherapi
remain
standard
care
major
patient
small
cell
lung
cancer
friday
novemb
terpsichor
educ
symposium
lung
cancer
small
cell
lung
cancer
gari
middleton
friday
novemb
terpsichor
educ
symposium
lung
cancer
small
cell
lung
cancer
ben
slotman
although
incid
small
cell
lung
cancer
sclc
declin
still
compris
lung
cancer
approxim
sclc
patient
present
distant
metastas
es
extens
stage
present
current
statu
futur
prospect
role
thorac
prophylact
cranial
irradi
discuss
standard
treatment
patient
without
distant
metastas
ls
limit
stage
combin
radiochemotherapi
outcom
number
studi
indic
radiotherapi
start
earli
given
concurr
chemotherapi
pignon
de
ruijsscher
twice
daili
radiotherapi
may
enabl
deliveri
requir
radiat
dose
short
time
accept
toxic
ongo
radiotherapi
gy
fraction
week
compar
fraction
radiotherapi
dose
gy
studi
investig
whether
high
dose
mainli
treatment
benefici
compar
gy
week
regimen
trial
arm
deliv
gy
fraction
week
gy
gy
daili
day
follow
gy
twice
daili
day
patient
ls
show
evid
diseas
progress
prophylact
cranial
irradi
pci
given
complet
chemotherapi
reduc
risk
brain
metastas
also
lead
improv
surviv
rate
auperin
neuropsycholog
evalu
shown
differ
neuropsycholog
function
patient
receiv
receiv
pci
recent
studi
dose
pci
reveal
benefit
increas
pci
dose
vs
gy
gy
fraction
remain
standard
le
pechoux
result
pci
ls
combin
even
higher
risk
brain
metastas
patient
es
prompt
us
investig
role
pci
respond
es
patient
well
patient
pci
significantli
reduc
risk
brain
metastas
also
increas
surviv
rate
slotman
failur
import
problem
patient
es
dutch
lung
cancer
group
rtog
initi
trial
role
thorac
radiotherapi
patient
es
sclc
respond
chemotherapi
crest
studi
patient
receiv
gy
fraction
thorac
lesion
complet
chemotherapi
studi
dose
gy
fraction
week
deliv
thorax
maximum
extracrani
site
friday
novemb
terpsichor
educ
symposium
lung
cancer
non
small
cell
lung
cancer
william
travi
except
field
lung
cancer
patholog
rel
static
past
sever
decad
major
advanc
diagnosi
cell
lung
cancer
nsclc
base
small
biopsi
andor
cytolog
area
lung
cancer
diagnosi
paradigm
shift
occur
pathologist
clinician
topic
import
major
patient
lung
cancer
present
unresect
diseas
diagnosi
establish
base
small
specimen
moreov
increas
use
minim
invas
biopsi
method
pathologist
ask
less
tissu
world
health
organ
classif
lung
tumor
address
lung
cancer
diagnosi
base
small
biopsi
cytolog
recommend
histolog
classif
resect
specimen
classif
cytolog
address
first
time
classif
small
biopsi
current
intern
recogn
standard
criteria
terminolog
diagnosi
lung
cancer
small
biopsi
import
decis
pathologist
small
biopsi
cytolog
histor
crucial
distinct
small
cell
lung
cancer
sclc
nsclc
defin
patient
complet
differ
clinic
tumor
behavior
manag
within
nsclc
import
clinic
reason
separ
squamou
cell
carcinoma
adenocarcinoma
histolog
type
exist
literatur
review
span
year
clinic
studi
evalu
chemotherapi
advanc
nsclc
weak
associ
histolog
therapeut
none
studi
report
formal
test
treatment
histolog
interact
therefor
older
studi
clear
evid
histolog
prognost
independ
treatment
predict
role
associ
effect
specif
treatment
patient
nsclc
recent
chang
three
clinic
observ
advanc
lung
cancer
patient
provid
reason
pathologist
chang
practic
make
better
attempt
distinguish
adenocarcinoma
squamou
cell
carcinoma
first
patient
advanc
lung
cancer
treat
bevacizumab
increas
risk
hemorrhag
squamou
cell
second
patient
adenocarcinoma
nsclc
otherwis
specifi
report
larg
cell
carcinoma
studi
respond
significantli
better
pemetrex
squamou
cell
third
egfr
mutat
strongli
associ
adenocarcinoma
histolog
patient
advanc
nsclc
egfr
mutat
better
outcom
respons
tyrosin
kinas
inhibitor
tki
first
line
therapi
patient
without
egfr
mutat
seem
better
outcom
importantli
studi
histolog
classif
base
sole
light
microscopi
without
mucin
stain
immunohistochemistri
special
techniqu
util
classifi
tumor
new
lung
adenocarcinoma
classif
publish
intern
associ
studi
lung
cancer
iaslc
american
thorac
societi
at
european
respiratori
societi
er
new
classif
present
algorithm
recommend
terminolog
special
stain
approach
tissu
refer
wd
brambilla
e
hk
harri
cc
patholog
genet
tumour
lung
pleura
thymu
heart
lyon
franc
iarc
press
wd
colbi
tv
corrin
b
shimosato
brambilla
e
histolog
type
lung
pleural
tumor
berlin
springer
fr
spreafico
novello
wood
md
simm
l
papotti
prognost
predict
role
histolog
advanc
cell
lung
cancer
literatur
review
j
thorac
oncol
dh
fehrenbach
l
novotni
wf
et
al
random
phase
ii
trial
compar
bevacizumab
plu
carboplatin
paclitaxel
carboplatin
paclitaxel
alon
previous
untreat
local
advanc
metastat
lung
cancer
j
clin
oncol
g
hanna
n
fossella
f
et
al
differenti
efficaci
pemetrex
accord
nsclc
histolog
review
two
phase
iii
studi
oncologist
gv
parikh
p
von
pawel
j
et
al
phase
iii
studi
compar
cisplatin
plu
gemcitabin
cisplatin
plu
pemetrex
patient
lung
cancer
j
clin
oncol
brodowicz
zielinski
c
et
al
mainten
pemetrex
plu
best
support
care
versu
placebo
plu
best
support
care
lung
cancer
randomis
phase
studi
lancet
ts
wu
yl
thongprasert
et
al
gefitinib
pulmonari
adenocarcinoma
n
engl
j
med
morita
yatab
et
al
gefitinib
versu
cisplatin
plu
docetaxel
patient
lung
cancer
harbour
mutat
epiderm
growth
factor
receptor
open
label
randomis
phase
trial
lancet
oncol
wd
brambilla
e
noguchi
et
al
new
iaslcats
intern
multidisciplinari
lung
adenocarcinoma
classif
jthorac
oncol
press
friday
novemb
terpsichor
educ
symposium
lung
cancer
non
small
cell
lung
cancer
jan
p
van
meerbeeck
incident
case
lung
cancer
us
cell
variant
nsclc
approxim
present
diagnosi
locoregion
involv
latter
mean
tumor
spread
confin
lung
surround
structur
without
clinic
evid
dissemin
extens
vari
tumor
local
abut
chest
wall
diaphragm
mediastinum
frank
invas
mediastin
tissu
organ
nodal
invas
either
ipsilater
lymph
node
supraclavicular
contralater
mediastin
lymphnod
although
extens
formal
barrier
radic
surgeri
eg
prefer
follow
adjuv
lesion
clinic
mediastin
lymph
node
invas
consid
beyond
limit
immedi
surgeri
refer
stage
iii
nsclc
subclassifi
iiia
whenev
node
involv
tumor
iiib
whenev
involv
present
correl
mediastin
lymphnod
recent
describ
overal
five
year
surviv
rate
local
advanc
lung
cancer
past
decad
gradual
shift
standard
care
select
patient
stage
iii
nsclc
radic
local
treatment
sequenti
administ
system
locoregion
treatment
present
concurr
chemoradiotherapi
role
surgeri
local
treatment
follow
induct
chemo
therapi
stage
recent
challeng
larg
random
trial
show
statist
signific
improv
overal
surviv
compar
definit
radiat
therapi
rt
role
surgeri
stage
iii
clinic
nodal
involv
henc
consid
limit
present
day
surviv
figur
select
patient
stage
iii
nsclc
treat
concurr
chemoradiotherapi
averag
median
month
year
rate
versu
month
sequenti
approach
factor
predict
outcom
perform
statu
stage
iiiab
weight
loss
patholog
downstag
mediastinum
andor
tumor
induct
treatment
relap
pattern
typic
show
modal
complet
control
tumor
patient
equal
number
patient
fail
intrathorac
extrathorac
improv
combin
modal
outcom
henc
come
improv
local
system
therapi
success
intervent
increas
local
control
rt
includ
dose
escal
alter
fraction
integr
concurr
chemotherapi
intervent
increas
tumor
cell
kill
varieti
mechan
inflict
initi
radiat
damag
decreas
repair
counteract
effect
prolifer
conclus
optim
treatment
local
advanc
nsclc
move
target
strong
convict
modern
radiotherapi
part
multimod
approach
stage
iii
patient
improv
outcom
last
decad
seen
advent
sever
novel
radiat
techniqu
like
improv
local
control
deliveri
higher
radiat
dose
smaller
volum
allow
lesser
toxic
techniqu
mutual
exclus
instead
complimentari
implement
techniqu
need
clinic
trial
appropri
select
patient
take
account
much
differ
variabl
present
option
avail
refer
jemal
siegel
r
ward
e
et
al
ca
cancer
j
clin
mountain
cf
chest
chapet
kong
fm
quint
le
et
al
int
j
radiat
oncol
biol
phi
nsclc
collabor
group
brit
med
j
rolland
e
curran
wj
et
al
j
thor
oncol
abstract
van
meerbeeck
jp
kramer
gwpm
van
schil
pey
et
al
j
natl
cancer
inst
albain
ks
swann
rs
rusch
v
et
al
lancet
oncol
johnson
dh
rusch
vw
turrisi
j
nat
cancer
instit
robinson
la
ruckdeschel
jc
wagner
h
steven
cw
chest
le
chevali
arriagada
r
tarayr
et
al
j
natl
cancer
inst
blackstock
aw
govindan
r
j
clin
oncol
friday
novemb
erato
ab
lectur
lung
cancer
never
smoker
heather
wakele
tobacco
exposur
far
common
caus
lung
cancer
diseas
also
seen
without
smoke
histori
fact
women
lung
cancer
percentag
histori
smoke
rang
approxim
unit
state
asian
countri
given
overal
preval
lung
cancer
mean
lung
cancer
higher
incid
diseas
entiti
cervic
cancer
mortal
rate
dwarf
mani
malign
mani
specul
incid
lung
cancer
rise
though
data
difficult
obtain
due
lack
cancer
registri
captur
smoke
data
publish
literatur
contradictori
less
contradictori
data
indic
constitut
higher
percentag
women
lung
cancer
men
lung
cancer
higher
preval
adenocarcinoma
compar
squamou
cell
carcinoma
lung
cancer
racialethn
differ
diseas
higher
rate
seen
asia
caus
lung
cancer
remain
elus
postul
includ
secondhand
smoke
exhaust
vehicl
cook
fume
poorli
ventil
kitchen
radon
exposur
environment
toxin
asbesto
lesser
extent
genet
factor
regardless
caus
excit
research
identifi
specif
driver
mutat
certain
gene
account
approxim
half
lung
cancer
best
character
epiderm
growth
factor
receptor
egfr
tyrosin
kinas
inhibitor
egfr
develop
decad
ago
dramat
respons
seen
preferenti
patient
without
smoke
histori
led
discoveri
specif
mutat
egfr
approxim
patient
nsclc
percentag
closer
high
asian
lung
cancer
patient
mutat
lead
protein
constitut
turn
turn
drive
lung
cancer
turn
switch
erlotinib
gefitinib
lead
dramat
respons
though
unfortun
resist
develop
sever
month
year
recent
anaplast
lymphoma
kinas
fusion
protein
identifi
lung
cancer
patient
closer
smoke
histori
particularli
young
diseas
drug
crizotinib
work
dramat
patient
popul
though
resist
develop
time
molecular
differ
lung
cancer
smoke
histori
also
identifi
ongo
research
identifi
lung
cancer
import
diseas
entiti
excit
research
molecular
underpin
diseas
led
dramat
therapeut
advanc
hope
lead
therapeut
advanc
lung
cancer
patient
reduct
stigma
associ
diseas
thursday
novemb
erato
ab
lectur
impact
new
lung
cancer
stage
system
clinic
practic
clinic
research
peter
goldstraw
public
new
tnm
classif
alway
major
event
clinician
research
involv
studi
treatment
particular
cancer
especi
case
launch
edit
tnm
classif
lung
cancer
first
revis
year
radic
year
unfortun
scientif
rigour
analyt
process
requir
broke
convent
new
edit
retrospect
compat
earlier
edit
almost
certainli
case
futur
revis
collect
raw
data
recommend
futur
proof
data
long
term
edit
enact
januari
new
case
lung
cancer
classifi
new
edit
estim
case
would
result
differ
stage
assign
compar
edit
edit
first
incorpor
carcinoid
tumour
tnm
classif
emphasis
use
tnm
clinic
manag
trial
design
lung
cancer
sclc
provid
pathologist
first
standardis
definit
viscer
pleural
invas
provid
clinician
research
intern
agre
nodal
map
reconcil
discrep
previous
use
map
precis
defin
anatom
boundari
nodal
station
alongsid
new
map
recognis
recommend
mean
describ
region
lymph
node
involv
lung
cancer
standardis
import
edit
establish
minimum
number
lymph
node
remov
surgeon
examin
pathologist
establish
pn
categori
resect
case
anatom
extent
diseas
describ
tnm
classif
mandat
treatment
option
certainli
major
factor
decis
edit
incorpor
addit
size
new
case
addit
tumour
nodul
certain
locat
result
tnm
stage
group
upstag
close
align
stage
prognosi
situat
case
tradit
treat
surgic
upstag
edit
one
may
wonder
case
consid
adjuv
therapi
complet
resect
case
previous
consid
inoper
one
may
wonder
select
case
categori
consid
surgic
treatment
albeit
set
import
suggest
test
appropri
clinic
trial
chang
treatment
algorithm
accept
new
standard
care
refer
goldstraw
p
iaslc
stage
handbook
thorac
oncolog
ed
florida
usa
editorialrx
press
goldstraw
p
iaslc
stage
manual
thorac
oncolog
ed
florida
usa
editorialrx
press
goldstraw
p
crowley
jj
chanski
k
giroux
dj
groom
pa
r
et
al
iaslc
lung
cancer
stage
project
propos
revis
stage
group
forthcom
seventh
edit
tnm
classif
lung
cancer
j
thorac
oncol
kassi
es
vaporciyan
aa
swisher
sg
correa
bekel
bn
erasmu
jj
et
al
applic
revis
lung
cancer
stage
system
iaslc
stage
project
cancer
center
popul
journal
thorac
cardiovascular
surgeri
saturday
novemb
terpsichor
plenari
lectur
state
art
treatment
hodgkin
lymphoma
volker
diehl
hodgkin
lymphoma
hl
monoclon
asia
hl
rare
new
casesanno
wherea
western
countri
annual
incid
histor
aspect
manag
year
radiotherapi
mainstak
therapi
yield
cure
rate
local
ann
arbor
stage
advent
polychemotherapi
regimen
mopp
later
abvd
regimen
made
cure
possibl
even
advanc
stage
howev
unexpect
toxic
term
side
effect
radiat
mustard
cyclophoshamid
procarbazin
mopp
induc
secondari
leukemia
solid
tumor
amount
year
nearli
mitig
therapeut
breakthrough
modern
manag
strategi
hl
patient
today
modern
strategi
treatment
reach
cure
rate
nearli
stage
diseas
serv
model
manag
strategi
cancer
treatment
decis
base
diagnosi
base
suffici
represent
biopsi
anatom
extent
lymphoma
lesion
catagor
accord
ann
b
without
system
symptom
stage
without
risk
factor
earli
stage
risk
factor
bulk
cm
high
esr
b
lymph
node
area
extranod
involv
eortc
age
treat
cours
abvd
gy
pf
year
os
german
hodgkin
studi
group
experi
trial
pat
recruit
stage
b
risk
factor
intermedi
stage
beacopp
escal
abvd
abvd
gy
usa
intermedi
stage
accord
ghsg
experi
pf
os
data
abvd
around
pf
os
stage
iib
lmm
b
advanc
stage
abvd
gy
usa
canada
beacopp
escal
advanc
stage
ghsg
recruit
pat
pf
ys
os
usacanada
ys
pf
os
futur
perspect
multipl
intern
cooper
studi
ongo
evalu
role
impact
earli
respons
assess
cours
abvd
beacopp
tailor
therapi
individu
risk
patient
relapseprogress
need
escal
preserv
high
cure
rate
minim
long
term
sequela
like
secondari
neoplasia
endocrin
gonad
cardiac
pulmonari
complic
new
horizon
open
target
therapi
hl
lenalidomid
inhibitor
anti
antbodi
multipl
studi
start
global
test
promis
moleculesantibodi
relaps
set
well
induct
therapi
friday
novemb
erato
c
debat
adjuv
immunotherapi
malign
melanoma
alexand
eggermont
follow
phase
iii
adjuv
interferon
ifn
therapi
trial
intermedi
dose
ifn
idi
miu
low
dose
ifn
ldi
miu
conduct
tabul
interestingli
three
smallest
trial
scottish
pt
austrian
pt
german
pt
best
hr
caus
concern
view
consist
wors
outcom
larg
trial
two
largest
trial
nordic
virtual
ident
hr
idi
trial
interestingli
virtual
ident
hr
rf
pt
trial
overal
ldi
idi
effect
stage
ii
stage
iib
stage
iii
littl
evid
efficaci
stage
iii
palpabl
nodal
involv
larger
trial
provid
consist
data
regard
impact
ifn
df
dfiand
rf
well
os
interestingli
lower
stage
ulcer
primari
independ
predict
factor
outcom
eortc
friday
novemb
erato
c
debat
adjuv
immunotherapi
malign
melanoma
helen
goga
although
cutan
malign
melanoma
least
common
form
skin
cancer
account
skin
cancer
death
therapeut
manag
cutan
melanoma
one
challeng
issu
oncologist
melanoma
among
solid
malign
refractori
medic
therapi
make
earli
diagnosi
surgic
remov
primari
tumor
virtual
cur
approach
current
avail
patient
melanoma
american
joint
committe
cancer
ajcc
tnme
stage
ii
stage
iii
diseas
rate
diseas
recurr
rang
overal
surviv
os
vari
agent
current
approv
adjuv
therapi
patient
interferon
alpha
dosag
schedul
rout
administr
vari
consider
among
variou
trial
purpos
interpret
use
consid
subhead
trial
high
dosag
defin
dosag
subcutan
andor
intraven
low
dosag
defin
dosag
muday
defin
intermedi
hdi
regimen
design
ecog
uniqu
schedul
compris
initi
intraven
induct
phase
last
week
follow
prolong
subcutan
administ
high
dose
treatment
month
rational
behind
develop
regimen
twofold
deliv
maxim
toler
dose
finit
period
time
decreas
potenti
form
antibodi
administr
intraven
compon
regimen
test
four
random
ecog
intergroup
trial
first
pivot
studi
accept
fda
oncolog
drug
advisori
committe
basi
licensur
intron
first
effect
adjuv
therapi
melanoma
follow
resect
diseas
patient
deep
primari
ajcc
stage
iib
region
lymph
node
metastat
diseas
ajcc
stage
iii
diseas
first
random
trial
regimen
ecog
trial
enrol
patient
median
nearli
year
median
surviv
significantli
prolong
year
surviv
year
respect
overal
trial
toxic
regimen
consider
dose
modif
delay
requir
nearli
two
third
patient
first
month
treatment
half
subject
last
month
therapi
second
intergroup
trial
patient
accru
complet
june
lack
overal
surviv
benefit
hdi
observ
despit
improv
surviv
lack
overal
surviv
benefit
gener
signific
controversi
regard
benefit
hdi
regimen
data
third
trial
address
adjuv
use
hdi
year
demonstr
highli
signific
surviv
overal
surviv
benefit
patient
treat
patient
assign
gmk
vaccin
current
effort
us
intern
cooper
group
dissect
critic
compon
regimen
compar
regimen
monoclon
antibodi
saturday
novemb
terpsichor
b
current
issu
oncolog
intervent
radiolog
cancer
thierri
de
liver
common
site
metastasi
colorect
cancer
liver
metastas
often
stepwis
pattern
metastat
progress
often
caus
death
thu
justifi
local
treatment
often
associ
system
treatment
hepat
chemotherapi
iahc
take
advantag
liver
vascular
arteri
portal
tumor
grow
liver
nearli
exclus
fed
arteri
blood
iahc
fu
fudr
demonstr
better
respons
rate
iahc
iv
treatment
howev
two
trial
demonstr
moder
benefit
surviv
group
cancer
intra
arteri
chemotherapi
oxaliplatinum
heavili
pretreat
patientsoff
promis
respons
rate
recent
iah
oxaliplatijn
plu
iv
cetuximab
kra
wild
first
line
therapi
demonstr
overal
respons
rate
convers
surgic
patient
similar
respons
rate
surgic
convers
report
hiac
fudr
combin
system
oxalliplatin
irinotecan
percutan
insert
cathet
iahc
demonstr
feasibl
better
overal
permeabl
surgic
one
vs
cours
chemoembol
combin
arteri
drug
deliveri
vascular
occlus
experiment
demonstr
better
pharmacolog
profil
iah
iv
inject
use
drug
elut
beadsrespons
rate
respons
rate
improv
qualiti
life
advers
reaction
radiomebol
inject
load
glass
resin
microspher
salvag
therapi
heavili
pretreat
patient
unresect
colorect
liver
metastas
fail
line
chemotherapi
patient
demonstr
median
surviv
month
respond
month
p
morpholog
respons
found
patient
accord
recist
cea
level
decreas
patient
rct
patient
studi
iahc
fudr
vs
iahc
show
respons
rate
month
time
progress
respect
today
larg
scale
patient
random
control
trial
sirflox
compar
vs
fir
line
treatment
ongo
indic
time
therapi
within
cours
non
surgic
liver
metastat
diseas
remain
discuss
today
treatment
move
salvag
therapi
toward
earli
use
cours
diseas
hope
propos
earli
possibl
effici
treatment
abl
downstag
patient
convert
non
surgic
candid
surgic
candid
could
achiev
case
two
recent
studi
inde
today
surgeri
remain
cur
treatment
colorect
cancer
metastas
saturday
novemb
terpsichor
plenari
lectur
state
art
use
biolog
adjuv
set
colon
cancer
aimeri
de
gramont
goal
adjuv
therapi
increas
cure
rate
cancer
erad
residu
micrometastasi
benefit
adjuv
therapi
colon
cancer
shown
fluoropyrimid
alon
combin
oxaliplatin
demonstr
activ
advanc
diseas
albeit
proven
efficaci
metastat
diseas
irinotecan
combin
could
show
advantag
term
surviv
adjuv
set
nsabp
avant
phase
iii
trial
evalu
bevacizumab
combin
chemotherapi
patient
stage
colon
cancer
nsabp
trial
compar
fortnightli
modifi
regimen
month
regimen
bevacizumab
everi
week
bevacizumab
alon
mainten
therapi
mgkg
everi
week
addit
month
contrari
advanc
diseas
arteri
ischem
event
gi
perfor
hemorrhag
associ
higher
frequenc
bevacizumab
arm
control
arm
toxic
significantli
increas
bevacizumab
hypertens
pain
proteinuria
wound
complic
addit
bevacizumab
modifi
folfox
result
statist
signific
prolong
df
df
vs
respect
hr
p
spite
transient
benefit
df
first
year
bevacizumab
util
avant
studi
compar
month
vs
month
bevacizumab
month
vs
xelox
month
bevacizumab
month
patient
stage
ii
iii
colon
cancer
advers
event
profil
compar
safeti
profil
metastat
diseas
nsabp
trial
efficaci
result
avail
late
us
intergroup
european
trial
evalu
folfox
chemotherapi
month
without
weekli
administr
cetuximab
patient
stage
iii
colon
cancer
whose
tumor
complet
remov
surgeri
result
present
asco
patient
wild
type
kra
tumor
benefit
cetuximab
df
arm
cetuximab
plu
arm
hr
p
trend
observ
overal
surviv
furthermor
patient
year
patient
mutat
kra
tumor
experienc
worst
outcom
cetuximab
chemotherapi
alon
note
cetuximab
ad
signific
toxic
chemotherapi
result
trial
yet
avail
thu
preliminari
result
first
trial
fail
improv
surviv
even
though
drug
activ
metastat
diseas
benefit
adjuv
therapi
might
predict
activ
advanc
set
determin
better
signal
launch
adjuv
trial
could
prevent
failur
adjuv
set
recruit
larg
number
patient
certainli
improv
understand
mechan
action
drug
tumor
biolog
look
biomark
select
popul
predict
benefit
therapi
could
larg
adjuv
trial
saturday
novemb
terpsichor
b
current
issu
oncolog
intervent
radiolog
cancer
christo
georgiad
introduct
current
western
countri
approxim
liver
transplant
perform
hcc
drop
risk
patient
await
liver
transplant
hcc
stand
transplant
liver
avail
expect
worsen
result
longer
wait
time
increas
drop
rate
aim
determin
whether
chemoembol
reduc
risk
maintain
patient
donor
liver
becom
avail
patient
method
consecut
hcc
patient
list
liver
transplant
accord
milan
criteria
underw
statist
compar
adjust
use
propens
score
wilcoxon
fisher
test
hcc
diagnos
biopsi
cirrhot
patient
hypervascular
liver
mass
afp
treat
patient
select
criteria
tumor
cm
larger
lesion
within
cm
plan
surgic
plane
patient
chemoembol
patient
compar
meld
score
tumor
sizenumb
afp
level
caus
cirrhosi
calcul
risk
drop
transplant
list
assign
transplant
time
drop
equal
probabl
patient
list
longer
patient
question
signific
level
obtain
calcul
simul
distribut
differ
permut
chemoembol
vs
assign
patient
estim
test
use
determin
surviv
rate
chemoembol
perform
experienc
intervent
radiologist
use
tripl
chemotherapi
cocktail
doxorubicin
mitomicin
c
cisplatin
follow
micromet
embospher
embol
procedur
repeat
everi
week
follow
mri
show
residu
viabl
tumor
enhanc
use
easl
criteria
result
median
follow
week
rang
date
diagnosi
chemoembol
group
risk
reduct
vs
chemoembol
signific
p
though
surviv
also
better
chemoembol
group
reach
statist
signific
like
studi
underpow
surviv
analysi
object
specif
surviv
chemoembol
group
respect
p
conclus
chemoembol
appear
result
signific
reduct
risk
drop
liver
transplant
list
patient
hcc
chemoembol
consid
hcc
patient
await
liver
transplant
whose
lesion
cm
larger
close
plan
surgic
plane
though
reach
statist
signific
tendenc
toward
longer
surviv
treat
group
saturday
novemb
terpsichor
b
current
issu
oncolog
intervent
radiolog
cancer
geschwind
saturday
novemb
terpsichor
b
current
issu
oncolog
intervent
radiolog
cancer
clotild
della
pina
term
tumor
ablat
defin
direct
applic
chemic
thermal
therapi
specif
focal
tumor
tumor
attempt
achiev
erad
substanti
tumor
destruct
although
tumor
ablat
procedur
perform
laparoscopi
surgeri
procedur
perform
percutan
approach
henc
sever
author
refer
procedur
percutan
therapi
concept
imag
guidanc
stress
titl
highlight
imag
guidanc
critic
success
therapi
past
year
sever
method
chemic
thermal
tumor
destruct
develop
clinic
test
thermal
abl
therapi
involv
clinic
practic
classifi
either
hypertherm
treatment
includ
radiofrequ
ablat
rfa
microwav
ablat
mwa
laser
ablat
cryoablat
thermal
damag
caus
heat
depend
tissu
temperatur
achiev
durat
heat
heat
tissu
minut
produc
irrevers
cellular
damag
temperatur
near
immedi
coagul
tissu
induc
irrevers
damag
mitochondri
cytosol
enzym
cell
tissu
vapor
carbon
hand
freez
tissu
temperatur
follow
rapid
thaw
result
cell
membran
disrupt
induc
cell
death
adequ
destruct
tumor
tissu
entir
target
volum
must
subject
cytotox
temperatur
among
method
rfa
current
establish
primari
abl
modal
institut
rfa
accept
best
therapeut
choic
patient
hepatocellular
carcinoma
liver
transplant
surgic
resect
suitabl
option
consid
viabl
altern
surgeri
inoper
patient
limit
hepat
metastat
diseas
especi
colorect
cancer
recent
rfa
demonstr
safe
valuabl
treatment
option
patient
unresect
medic
inoper
lung
malign
resect
remain
standard
therapi
cell
lung
cancer
nsclc
rfa
may
better
convent
radiat
treatment
individu
nsclc
initi
favor
outcom
encourag
combin
radiotherapi
rfa
especi
treat
larger
tumor
set
colorect
cancer
lung
metastas
surviv
rate
provid
rfa
select
patient
substanti
higher
obtain
chemotherapi
regimen
provid
indirect
evid
rfa
improv
surviv
patient
limit
lung
metastat
diseas
novel
techniqu
tumor
irrevers
electropor
light
activ
drug
potenti
overcom
limit
rfa
warrant
clinic
investig
efficaci
combin
therapi
includ
ablat
plu
administr
bead
thermal
sensit
drug
carrier
also
current
explor
thursday
novemb
terpsichor
b
scientif
symposium
antiangiogen
therapeut
strategi
cancer
inhibitor
dirk
arnold
thursday
novemb
terpsichor
scientif
symposium
cancer
translat
dilemma
diminish
cancer
vaccin
efficaci
madhav
v
dhodapkar
monoclon
antibodi
mab
emerg
effect
therapi
sever
cancer
recent
studi
sever
preclin
model
shown
fc
portion
antibodi
critic
efficaci
sever
set
engag
fc
receptor
mab
opson
cell
lead
activ
antibodi
depend
cytotox
prior
studi
other
shown
fcr
depend
pathway
also
critic
activ
adapt
immun
fcr
mediat
uptak
opson
tumor
cell
lead
mark
increas
gener
tumor
immun
dendrit
cell
fc
receptor
system
balanc
activ
inhibitori
receptor
steadi
state
condit
signal
via
inhibitori
receptor
domin
play
import
role
mediat
immun
toler
alter
balanc
toward
reduc
inhibitori
signal
lead
activ
immun
cell
dendrit
cell
dc
activ
type
interferon
respons
pathway
major
effect
immun
stimulatori
properti
dc
balanc
activatinginhibitori
receptor
therefor
play
role
regul
immun
effect
mab
therapi
inde
fcr
polymorph
strongli
link
surviv
follow
antibodi
rituximab
therapi
lymphoma
togeth
emerg
data
suggest
clinic
efficaci
mab
therapi
may
determin
direct
effect
tumor
cell
also
natur
recruit
immunolog
mechan
depend
larg
part
fc
portion
antibodi
consider
also
provid
biolog
basi
ration
combinatori
therapi
well
antibodi
engin
improv
efficaci
antibodi
therapi
anoth
concept
major
implic
immunotherapi
cancer
import
self
renew
pathway
stem
cancer
other
recent
shown
cell
target
pathway
involv
regul
stem
highli
effect
inhibit
growth
tumor
cell
cultur
preclin
studi
also
support
target
put
cancer
stem
cell
mice
presenc
spontan
cell
respons
embryon
stem
es
cell
gene
strong
predictor
favor
outcom
patient
monoclon
gammopathi
myeloma
immun
core
es
gene
may
much
common
previous
thought
readili
detect
healthi
individu
har
immun
gene
import
self
renew
tumor
cell
may
import
requir
elicit
durabl
protect
immun
cancer
vaccin
thursday
novemb
terpsichor
b
scientif
symposium
antiangiogen
therapeut
strategi
inhibitor
ulrich
hacker
thursday
novemb
terpsichor
scientif
symposium
cancer
translat
dilemma
diminish
cancer
vaccin
efficaci
thoma
thursday
novemb
terpsichor
b
scientif
symposium
antiangiogen
therapeut
strategi
cancer
inhibitor
sonja
loge
thursday
novemb
terpsichor
scientif
symposium
cancer
translat
dilemma
diminish
cancer
vaccin
efficaci
han
w
nijman
first
part
present
interact
tumor
cell
death
due
chemotherapi
radiotherapi
one
hand
induct
immun
respons
induc
cell
death
hand
achiev
optim
result
tumor
erad
elucid
postul
zitvogel
et
al
activ
calreticulin
exposur
pathway
import
mechan
activ
immun
system
treatment
classic
therapi
like
chemotherapi
thought
chemotherapi
gener
result
strong
reduct
major
compon
immun
system
therebi
harm
immun
system
readi
attack
tumor
hold
true
anymor
evolv
amount
evid
show
opposit
immunotherapi
combin
chemotherapi
might
effect
strategi
induc
long
live
antigen
specif
memori
cell
cisplatinum
next
paclitaxel
doxorubicin
drug
often
use
gynaecolog
malign
make
tumor
cell
suscept
granzym
b
depend
kill
cytotox
cell
chemotherapi
also
radiotherapi
prime
immun
respons
proof
principl
shown
diseas
like
prostat
cervic
cancer
second
part
present
enhanc
immunotherapi
treatment
monoclon
antibodi
discuss
one
exampl
treatment
anti
death
receptor
monoclon
antibodi
mab
combin
specif
immun
turn
promis
treatment
modal
result
highest
number
specif
cell
use
combin
next
death
receptor
antibodi
made
tumor
cell
also
suscept
ctl
kill
studi
tc
wu
other
initi
observ
mab
prime
tumor
specif
cell
mediat
immun
effect
mab
treatment
enhanc
ad
agonist
antibodi
costimulatori
molecul
underli
mechan
topic
research
moment
turn
b
cell
posit
dendrit
cell
might
play
role
idea
mab
induc
uptak
tumor
antigen
dendrit
cell
occur
optim
combin
therapi
need
explor
transgen
mice
combin
treatment
mab
antibodi
synergist
effect
suppress
spontan
aris
tumor
bortezomib
proteasom
inhibitor
promot
cancer
cell
death
combin
mab
whether
combin
would
enhanc
suppress
immunolog
respons
need
elucid
end
patient
might
benefit
combin
treatment
modal
includ
immunotherapi
radiotherapi
chemotherapi
without
target
therapi
thursday
novemb
terpsichor
scientif
symposium
cancer
translat
dilemma
diminish
cancer
vaccin
efficaci
marianna
nuti
vast
amount
inform
novel
knowledg
field
tumor
immunolog
last
year
increas
interest
defin
immunotherapeut
strategi
appli
cancer
therapi
immunotherapi
today
increas
attract
option
treatment
cancer
although
malign
presuppos
failur
host
respons
patient
develop
innat
adapt
immun
respons
cours
diseas
fact
measur
immun
prognost
signatur
defin
immunolog
histori
cancer
progress
becom
import
marker
use
defin
prognosi
establish
time
immunotherapi
intervent
immun
activ
appear
begin
earli
tumor
develop
progress
easili
boost
vaccin
howev
effect
tumor
rapid
least
compar
time
chemotherapi
treatment
need
time
activ
cognat
multipl
interact
ultim
lead
tumor
cell
kill
moreov
type
treatment
particularli
efficaci
presenc
minim
residu
diseas
sinc
heavi
tumor
burden
condit
oppos
strongli
type
immunolog
kill
base
contact
profit
advantag
lymphocyt
recircul
tissu
find
target
uniform
express
target
antigen
cancer
cell
may
also
essenti
sinc
mechan
epitop
spread
shown
occur
mice
human
contribut
significantli
tumor
reject
final
import
address
question
interact
standard
therapi
gold
standard
immunolog
intervent
approach
consid
way
opposit
chemotherapi
detriment
blood
cell
therefor
consid
separ
option
immunotherapi
today
anti
neoplast
drug
studi
induc
immunolog
death
outcom
pure
chemotherapi
trial
revis
result
combin
two
effect
cell
chemic
cytotox
consequ
immun
activ
moreov
surgeri
consid
optim
uniqu
way
reduc
tumor
deriv
immunosuppress
particularli
relev
gynecolog
cancer
exampl
ovarian
cancer
cytoreduct
appear
exert
benefici
system
effect
revert
immunosuppress
restor
immunolog
fit
patient
present
result
present
immunolog
microenviron
chang
occur
cancer
patient
convent
therapi
vaccin
discuss
light
possibl
implic
design
new
vaccin
strategi
propos
novel
criteria
biomark
evalu
monitor
immunotherapeut
clinic
trial
thursday
novemb
terpsichor
b
scientif
symposium
organ
ipo
break
new
develop
jame
brennan
background
thank
emerg
hospic
palli
care
physic
suffer
associ
cancer
never
better
control
psychosoci
suffer
associ
cancer
bear
much
closer
resembl
histor
imag
diseas
wast
pain
intern
societi
ipo
board
meet
held
vienna
member
unanim
endors
idea
distress
name
vital
sign
oncolog
past
decad
number
attempt
made
respond
cancer
distress
field
gradual
move
away
idea
distress
sensibl
equat
psychopatholog
day
gener
agre
distress
concept
involv
physic
psycholog
social
spiritu
caus
oncolog
servic
respond
distress
vital
sign
challeng
effici
effect
yet
human
uk
number
region
cancer
centr
adapt
us
nccn
distress
thermomet
develop
basi
screen
measur
form
triag
paper
describ
associ
develop
report
data
studi
valid
problem
list
pl
screen
tool
method
publish
version
pl
item
along
modif
made
uk
research
scrutinis
focu
group
compris
clinic
staff
group
examin
intellig
ambigu
potenti
redund
item
sometim
make
altern
suggest
pool
item
result
candid
item
sent
post
particip
ask
endors
item
sourc
concern
distress
recent
treatment
result
pl
particip
mix
cancer
patient
recent
finish
treatment
respons
obtain
written
femal
result
frequent
endors
item
fatigu
exhaust
extrem
tired
worri
fear
anxieti
sleep
problem
new
item
commonli
endors
memori
concentr
loneli
isol
suggest
item
routin
includ
screen
pl
discuss
health
servic
respond
cancer
distress
must
first
ask
right
question
patient
view
patient
reluct
volunt
concern
prepar
proactiv
also
essenti
screen
distress
accept
patient
languag
use
easili
understood
screen
method
present
paper
offer
potenti
effici
way
identifi
respond
cancer
distress
thu
far
warmli
welcom
patient
staff
alik
thursday
novemb
terpsichor
b
scientif
symposium
organ
ipo
break
new
develop
clare
moynihan
background
rel
littl
work
carri
men
cancer
women
overwhelmingli
repres
aspect
psychosoci
oncolog
surpris
consid
equal
act
final
pass
year
unit
kingdom
state
import
attend
gender
men
women
need
respect
cancer
care
moreov
rel
littl
known
regard
way
men
particip
adher
randomis
clinic
trial
involv
import
question
commun
littl
known
rest
deficit
model
patient
shown
misunderstand
import
facet
clinic
trial
thu
lead
inadequ
patient
sampl
sometim
result
curtail
expens
endeavour
method
recent
work
carri
research
deploy
qualit
methodolog
attempt
gain
insight
way
men
comprehend
gener
aspect
cancer
care
particular
concept
procedur
randomis
way
men
commun
reaction
comprehens
trial
procedur
reason
accept
declin
randomis
becom
import
focu
interest
particip
background
data
present
work
carri
men
prostat
cancer
invit
join
clinic
trial
recent
qualit
studi
investig
men
bladder
cancer
invit
join
complic
randomis
trial
form
main
thrust
talk
result
gener
men
women
may
similar
need
term
commun
howev
area
men
appear
prefer
certain
way
attend
particularli
evid
term
clinic
trial
studi
carri
mani
men
made
ration
self
serv
decis
declin
randomis
howev
other
shown
misunderstand
concept
procedur
led
accept
refus
randomis
cast
doubt
valid
trial
incap
understand
faulti
commun
procedur
appear
match
men
need
coercion
lack
time
make
decis
inform
overload
discusson
rather
utilis
deficit
model
way
patient
comprehend
concept
procedur
clinic
trial
import
address
way
men
may
wish
particip
trial
cancer
care
gener
clinician
health
profession
requir
look
practic
convey
complic
messag
situat
part
entir
new
consum
cancer
care
thursday
novemb
terpsichor
b
scientif
symposium
organ
ipo
break
new
develop
maggi
watson
background
number
older
cancer
patient
expect
doubl
older
patient
perceiv
group
becom
major
use
group
cancer
servic
futur
recent
chang
european
law
requir
cancer
patient
receiv
optim
care
regardless
age
examin
age
issu
studi
clarifi
support
need
accord
age
differ
physic
social
circumst
mean
need
older
patient
like
differ
younger
patient
differ
function
impair
social
support
network
lower
incom
associ
age
contribut
differ
support
psychosoci
need
issu
introduc
briefli
overview
alongsid
report
detail
studi
aim
clarifi
support
care
need
elderli
cancer
patient
research
question
psychosoci
inform
support
care
need
elderli
differ
younger
patient
point
differ
accord
age
method
prospect
questionnair
survey
methodolog
use
support
care
need
survey
scn
inform
satisfact
questionnair
short
form
isc
eortc
qlq
function
global
ql
subscal
particip
n
patient
n
senior
n
assess
baselin
month
includ
breast
gi
gu
lung
cancer
patient
result
data
present
baselin
characterist
sampl
comparison
senior
earli
period
follow
diagnosi
discuss
find
help
guid
develop
care
oncolog
meet
grow
need
age
popul
age
per
se
must
criterion
care
recognis
elderli
may
specif
need
oncolog
servic
need
increasingli
tailor
need
saturday
novemb
terpsichor
plenari
lectur
standard
care
treatment
chemotherapi
induc
nausea
vomit
cinv
matti
aapro
vomit
especi
nausea
continu
two
distress
side
effect
cancer
chemotherapi
spite
progress
made
sinc
earli
recommend
optim
antiemet
prophylaxi
patient
submit
chemotherapi
radiotherapi
suggest
mani
group
multin
asssoci
support
care
cancer
recent
publish
along
european
societi
fot
intern
medecin
posit
paper
present
base
conclus
paper
also
discuss
question
still
need
address
defin
emetogen
chemotherapi
agent
framework
defin
antiemet
treatment
guidelin
principl
use
antiemet
drug
prevent
nausea
vomit
induc
chemotherapi
follow
use
lowest
test
fulli
effect
dose
schedul
better
singl
dose
begin
chemotherapi
advers
effect
agent
compar
intraven
oral
formul
equal
effect
safe
prevent
acut
nausea
vomit
follow
chemotherapi
high
emet
risk
includ
anthracyclin
cyclophosphamid
combin
regimen
includ
singl
dose
receptor
antagonist
dexamethason
fo
aprepit
given
chemotherapi
recommend
guidelin
recommend
patient
receiv
highli
moder
emetogen
chemotherapi
receiv
antiemet
prevent
delay
nausea
vomit
palonosetron
superior
receptor
antagonist
receptor
antagonist
use
therefor
prevent
acut
nausea
vomit
induc
moder
emetogen
chemotherapi
combin
palonosetron
plu
dexamethason
recommend
standard
prophylaxi
dexamethason
substitut
corticosteroid
avail
aprepit
avail
women
receiv
combin
anthracyclin
plu
cyclophosphamid
receiv
combin
palonosetron
plu
dexamethason
small
studi
carri
patient
receiv
multipl
day
chemotherapi
prefer
use
maxim
effect
antiemet
first
line
therapi
rather
withhold
effect
antiemet
later
use
time
antiemet
failur
rescu
antiemet
treatment
done
number
approach
includ
switch
differ
receptor
antagonist
ad
agent
dopamin
antagonist
benzodiazepin
anticipatori
nausea
vomit
wide
believ
learn
respons
chemotherapi
develop
patient
fourth
treatment
cycl
difficult
control
pharmacolog
mean
therefor
recommend
best
approach
treatment
anticipatori
emesi
best
possibl
control
acut
delay
emesi
saturday
novemb
terpsichor
current
issu
oncolog
manag
cancer
pain
janet
l
abrahm
pain
reliev
without
excess
sedat
cancer
patient
initi
step
includ
comprehens
patient
assess
make
diagnosi
caus
pain
even
patient
underli
caus
revers
patient
report
pain
may
reflect
underli
tissu
damag
may
also
reflect
sourc
suffer
includ
emot
psycholog
spiritu
existenti
injuri
mean
pain
alter
intens
pain
follow
cur
resect
like
much
better
toler
pain
aris
progress
diseas
oncologist
oncolog
nurs
practition
must
therefor
address
pain
sourc
collabor
social
worker
psychologist
nurs
clergi
crucial
reliev
caus
distress
present
exacerb
experi
pain
pharmacolog
agent
sever
class
usual
requir
patient
achiev
pain
relief
agent
nsaid
glucocorticoid
adjuv
agent
specif
bone
neuropath
pain
opioid
opioid
avail
greek
physician
obtain
requir
permit
includ
oral
intraven
morphin
oral
morphin
transderm
fentanyl
anoth
speaker
discuss
treatment
bone
pain
present
review
util
side
effect
agent
use
pain
caus
muscl
tissu
injuri
neuropath
pain
agent
includ
nsaid
glucocorticoid
neuropath
adjuv
agent
opioid
fear
addict
prevent
cancer
patient
take
opioid
need
actual
cancer
patient
rare
becom
addict
opioid
use
reliev
pain
discuss
distinct
addict
physiolog
toler
way
encourag
cancer
patient
acquir
permit
need
take
opioid
despit
famili
fear
also
review
manag
patient
pain
crisi
use
oral
intraven
morphin
convert
patient
whose
pain
reliev
intraven
morphin
dose
oral
morphin
transderm
fentanyl
eg
vice
versa
prevent
treat
common
side
effect
ie
constip
nausea
sedat
pain
must
also
distinguish
delirium
mani
agent
use
reliev
pain
also
caus
delirium
also
review
therefor
metabol
pharmacolog
predispos
factor
caus
delirium
clinic
present
hyperact
delirium
done
revers
delirium
sinc
pain
exacerb
anxieti
depress
briefli
review
agent
friday
novemb
terpsichor
b
educ
symposium
infect
cancer
patient
mickael
aoun
overshadow
long
fulmin
bacteri
fungal
infect
viral
agent
wit
cancer
patient
increas
awar
last
decad
new
approach
diagnosi
base
molecular
biolog
method
new
antivir
therapeut
modal
develop
either
directli
caus
damag
indirectli
facilit
bacteri
fungal
infect
viral
agent
contribut
increas
morbid
mortal
cancer
patient
although
suscept
common
virus
infect
gener
popul
complic
cancer
patient
prone
devast
diseas
gener
sever
chronic
latent
viral
infect
global
epidemiolog
data
viral
infect
cancer
patient
sever
studi
focus
haematolog
malign
mainli
hematopoiet
transplant
hsct
last
review
caus
fever
cancer
patient
viral
caus
repres
howev
estim
sinc
mani
viral
infect
document
microbiolog
main
site
involv
includ
respiratori
tract
tract
central
nervou
system
pneumonia
one
common
infecti
complic
cancer
patient
receiv
chemotherapi
respiratori
virus
increasingli
recogn
import
pathogen
respons
sever
lower
respiratori
tract
infect
multiplex
polymeras
chain
reaction
nucleic
acid
sequenc
base
amplif
method
markedli
improv
detect
respiratori
virus
includ
old
one
influenza
parainfluenza
virus
respiratori
synciti
virus
rsv
adenovirus
new
one
human
metapneumoviru
coronaviru
rhinovirus
associ
mortal
cancer
patient
highli
variabl
highest
rate
report
hematopoiet
stem
cell
transplant
recipi
vaccin
contact
isol
import
prevent
measur
oseltamivir
iv
peramivir
evalu
sever
influenza
pneumonia
iv
oral
ribavirin
increasingli
use
parainfluenza
rsv
human
metapneumoviru
adenoviru
viral
infect
frequent
pediatr
cancer
popul
although
specif
treatment
epidem
viral
gastroenter
caus
noroviru
rotaviru
astroviru
identif
import
infect
control
measur
order
avoid
nosocomi
transmiss
herpet
mucos
common
cancer
patient
earli
treatment
acyclovir
almost
elimin
damag
previous
report
herp
simplex
pneumonia
hepat
ulcer
esophag
may
uncommonli
associ
herpet
mucos
rare
occas
highli
immunosuppress
patient
cytomegaloviru
could
caus
agent
viral
coliti
either
due
cytomegaloviru
human
herp
viru
enter
adenoviru
could
either
local
part
dissemin
diseas
viral
hepat
cancer
patient
major
concern
could
either
associ
dissemin
diseas
due
cytomegaloviru
adenoviru
ebv
due
reaction
hepat
virus
b
c
e
increas
evid
show
carrier
hepat
b
candid
chemotherapi
receiv
therapi
lamivudin
adefovir
viral
enceph
mening
cancer
patient
seriou
complic
sever
virus
implic
includ
herp
viru
herp
simplex
cmv
ebv
polyomaviru
jc
respons
progress
multifoc
occur
haematolog
malign
patient
llc
hodgkin
lymphoma
hsct
friday
novemb
terpsichor
b
educ
symposium
infect
cancer
patient
jean
klasterski
lung
cancer
cell
tumor
nsclc
present
lead
caus
account
death
first
progress
manag
nsclc
demonstr
favour
impact
platinum
therapi
surviv
qualiti
life
today
combin
platinum
deriv
follow
agent
docetaxel
paclitaxel
gemcitabin
vinorelbin
premetrex
continu
standard
care
advanc
metastat
nsclc
anoth
import
advanc
demonstr
adjuv
chemotherapi
prolong
surviv
signific
proport
patient
stage
ii
iiia
nsclc
underw
success
resect
tumor
recent
major
step
word
better
manag
nsclc
recognit
epiderm
growth
factor
egf
famili
play
import
role
tumorigen
process
frequent
overexpress
develop
progress
nsclc
actual
somat
mutat
identifi
tyrosin
kinas
domain
egfr
predict
signific
respons
egfr
inhibitor
gefitinib
erlotinib
mani
genet
abnorm
vegf
overexpress
kra
braf
mutat
amplif
etc
provid
better
understand
nsclc
carcinogenesi
could
use
prognost
factor
target
therapi
hope
therapi
nsclc
increasingli
becom
person
base
specif
featur
tumor
patient
tremend
laboratori
clinic
effort
achiev
better
manag
nsclc
howev
cloud
major
case
lung
cancer
due
tobacco
use
make
highli
prevent
diseas
thursday
novemb
terpsichor
plenari
lectur
erythropoiesi
stimul
agent
esa
cancer
patient
stand
today
iain
macdougal
anaemia
common
cancer
patient
exacerb
chemotherapi
neg
effect
surviv
contribut
fatigu
associ
cancer
mani
patient
requir
red
cell
transfus
advent
esa
therapi
brought
hope
may
effect
treatment
anaemia
would
reduc
need
blood
transfus
also
decreas
anaem
symptom
four
relev
issu
relat
use
esa
cancer
esa
enhanc
tumour
progress
due
stimul
tumour
cell
epo
receptor
esa
increas
risk
venou
thromboembol
malign
esa
impact
surviv
cancer
esa
improv
patient
cancer
last
year
begun
elucid
answer
question
earli
studi
breast
cancer
head
neck
malign
rais
safeti
concern
esa
therapi
although
studi
shown
mrna
isol
tumour
cell
much
harder
definit
show
presenc
epo
receptor
protein
due
lack
specif
antibodi
erythropoietin
receptor
also
question
whether
erythropoietin
receptor
tumour
cell
function
although
vitro
evid
show
enhanc
tumour
growth
erythropoietin
vivo
studi
less
convinc
thromboembol
common
event
cancer
patient
lead
caus
death
data
oncolog
well
nephrolog
literatur
suggest
enhanc
risk
thromboembol
esa
therapi
may
due
effect
platelet
function
endotheli
cell
activ
nitric
oxid
scaveng
data
nephrolog
oncolog
literatur
suggest
may
reduc
surviv
use
esa
therapi
current
malign
previou
histori
cancer
part
reason
increas
risk
thrombot
event
associ
use
esa
therapi
anaemia
associ
reduc
cancer
patient
esa
therapi
may
improv
fatigu
energi
score
cancer
patient
anaemia
variou
tool
use
assess
includ
lasa
score
improv
occur
possibl
gdl
gdl
less
addit
improv
also
evid
use
esa
therapi
reduc
requir
advers
affect
associ
blood
transfus
mani
therapi
use
esa
cancer
patient
fine
balanc
risk
benefit
certainli
potenti
benefit
mani
patient
risk
associ
use
set
must
acknowledg
particularli
increas
thromboembol
reduc
surviv
come
long
way
sinc
earli
three
studi
enrol
total
patient
conduct
satisfi
fda
grant
approv
use
recombin
erythropoietin
cancer
patient
present
day
sever
larg
cochran
perform
ten
thousand
cancer
patient
possibl
risk
esa
treatment
use
within
constraint
label
saturday
novemb
terpsichor
current
issu
oncolog
manag
cancer
pain
patrick
w
mantyh
friday
novemb
terpsichor
b
educ
symposium
infect
cancer
patient
kenneth
v
rolston
introduct
patient
cancer
develop
bacteri
infect
frequent
especi
exclus
episod
neutropenia
current
organ
predomin
bacteri
pathogen
caus
bacterem
infect
bacteri
infect
overal
polymicrobi
infect
less
frequent
associ
great
morbid
mortal
heavi
microbi
usag
mani
cancer
patient
creat
select
pressur
lead
emerg
resist
organ
sever
recent
report
therapeut
option
organ
limit
new
drug
develop
standstil
consequ
antimicrobi
stewardship
becom
import
aspect
manag
patient
bacteria
staphylococci
predomin
organ
caus
infect
cancer
patient
almost
methicillin
aureu
isol
methicillin
resist
vancomycin
use
agent
choic
treatment
infect
caus
staphylococci
recent
clinic
failur
vancomycin
encount
even
organ
consid
suscept
sever
reason
put
forward
includ
increas
mic
reduc
bactercid
activ
secondari
alter
agr
mechan
toler
vancomycin
altern
agent
includ
linezolid
daptomycin
telavancin
enterococci
common
pathogen
cancer
patient
isol
fecal
colon
vre
uncommon
patient
hematolog
malign
patient
develop
febril
neutropenia
empir
coverag
vre
might
prudent
current
linezolid
daptomycin
quinupristindalfopristin
agent
proven
clinic
activ
vre
import
pathogen
includ
streptococci
viridan
group
streptococci
vg
streptococcu
pneumonia
streptococci
although
streptococci
remain
penicillin
suscept
vg
pneumonia
often
overtli
resist
penicillin
bacteria
escherichia
coli
klebsiella
speci
pseudomona
aeruginosa
remain
three
common
pathogen
mani
organ
produc
esbl
render
resist
except
carbapenem
widespread
use
quinolon
prophylaxi
cancer
patient
led
emerg
quinolon
resist
e
coli
also
appear
increas
virul
klebsiella
organ
shown
produc
kpc
enzym
render
resist
carbapenem
pseudomona
aeruginosa
isol
acquir
multipl
resist
mechan
render
resist
known
antimicrobi
agent
includ
colistin
polymyxin
stenotrophomona
maltophilia
intrins
resist
mani
antimicrobi
increas
resist
rate
report
trimethoprim
sulfamethoxazol
long
consid
agent
choic
tigecyclin
consid
main
altern
option
treatment
bacteria
quit
limit
pipelin
new
drug
develop
remain
quit
dri
consequ
antimicrobi
stewardship
strict
adher
infect
control
practic
becom
increasingli
import
today
environ
friday
novemb
terpsichor
b
educ
symposium
infect
cancer
patient
georg
samoni
invas
fungal
infect
ifi
repres
major
threat
cancer
immunosuppress
patient
especi
suffer
hematolog
malign
chemotherapi
radiat
therapi
administr
sever
immunosuppress
agent
antimicrobi
agent
transplant
surgic
procedur
use
devic
among
predispos
factor
develop
ifi
candida
spp
recogn
caus
infect
alreadi
decad
ago
cryptococcu
spp
also
observ
patient
lymphoma
aspergillu
spp
recogn
later
threaten
organ
leukem
patient
zygomycet
fusarium
spp
becom
appar
rather
recent
major
risk
although
mani
new
diagnost
method
tool
develop
diagnosi
ifi
often
problemat
mani
time
event
henc
prophylaxi
infect
paramount
import
especi
patient
prolong
profound
immunosuppress
last
decad
new
antifung
drug
enrich
armamentarium
although
fight
fungi
start
five
decad
ago
amphotericin
b
step
ahead
achiev
first
azol
ketoconazol
miconazol
minim
impact
ifi
drug
whowev
herald
product
azol
compound
fluconazol
play
major
role
candida
itraconazol
effect
also
aspergillu
new
lipid
liposom
formul
amphotericin
b
gave
new
possibl
treat
wide
spectrum
fungal
diseas
formul
still
use
effect
therapeut
modal
product
newer
azol
voriconazol
made
differ
treatment
aspergillosi
posaconazol
broad
spectrum
offer
new
weapon
ifi
new
class
echinocandin
includ
caspofungin
micafungin
anidulafungin
broaden
even
antifung
armamentarium
howev
despit
develop
effect
drug
cancer
patient
remain
sensit
host
immunosuppress
minim
activ
antifung
agent
henc
infecti
diseas
commun
look
forward
new
compound
well
result
ongo
clinic
trail
assess
activ
combin
antifung
treatment
must
emphas
howev
restor
immun
system
possibl
remain
cornerston
treatment
prophylaxi
fungal
infect
patient
neoplast
diseas
saturday
novemb
terpsichor
current
issu
oncolog
manag
cancer
pain
jami
h
von
roenn
pain
one
fear
common
complic
advanc
cancer
fortun
major
patient
achiev
effect
relief
pain
util
standard
approach
pain
manag
minor
patient
metastat
diseas
curabl
cancer
effect
antineoplast
therapi
cure
cancer
gener
lead
resolut
pain
unfortun
major
patient
metastat
diseas
cure
current
avail
therapi
patient
incur
cancer
pain
manag
pain
essenti
compon
optim
cancer
care
frequent
type
pain
patient
metastat
diseas
bone
pain
secondari
osseou
metastas
mainstay
treatment
analges
antineoplast
treatment
provid
signific
benefit
radiat
therapi
oncolog
group
demonstr
extern
beam
radiat
therapi
whether
given
singl
multipl
fraction
provid
complet
partial
relief
pain
osseou
metastas
patient
overal
result
better
singl
sight
pain
treatment
extens
multifoc
osseou
metastas
bisphosphon
decreas
delay
occurr
skelet
fractur
metastat
bone
diseas
improv
pain
control
limit
degre
cancer
pain
relat
bone
metastasi
radiat
therapi
usual
treatment
choic
pharmacolog
treatment
treatment
choic
patient
advanc
diseas
multipl
site
pain
purport
goal
chemotherapi
patient
advanc
diseas
provid
symptom
palliat
howev
major
clinic
trial
pharmacolog
agent
assess
effect
treatment
advanc
diseas
base
tumor
shrinkag
patient
metastat
breast
cancer
random
trial
evalu
associ
symptom
improv
object
tumor
respons
pain
one
symptom
improv
patient
complet
partial
respons
treatment
relationship
object
tumor
respons
symptom
improv
evalu
diseas
site
data
impact
chemotherapi
pain
limit
outcom
may
vari
primari
site
number
excel
exampl
pain
relief
pharmacolog
treatment
cancer
accept
gemcitabin
treatment
pancreat
cancer
base
impact
symptom
control
qualiti
life
util
composit
measur
pain
perform
statu
weight
trial
prostat
cancer
incorpor
palli
endpoint
includ
pain
control
primari
outcom
measur
data
also
avail
tumor
site
